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ABSTRACT 
 
Animal models have been relevant to study the molecular mechanisms of 
cancer and to develop new antitumor agents. Anyway, the huge divergence in 
mouse and human evolution made difficult the translation of the gained 
achievements in preclinical mouse based studies. The generation of clinically 
relevant murine models requires their humanization both concerning the 
creation of transgenic models and the generation of humanized mice in which 
to engraft a functional human immune system, and reproduce the physiological 
effects and molecular mechanisms of growth and metastasization of human 
tumors. In particular, the availability of genotypically stable immunodepressed 
mice able to accept tumor injection and allow human tumor growth and 
metastasization would be important to develop anti-tumor and anti-metastatic 
strategies. Recently, Rag2-/-;γc-/- mice, double knockout for genes involved in 
lymphocyte differentiation, had been developed (CIEA, Central Institute for 
Experimental Animals, Kawasaki, Japan). Studies of human sarcoma 
metastasization in Rag2-/-;γc-/- mice (lacking B, T and NK functionality) 
revealed their high metastatic efficiency and allowed the expression of human 
metastatic phenotypes not detectable in the conventionally used nude murine 
model. In vitro analysis to investigate the molecular mechanisms involved in 
the specific pattern of human sarcomas metastasization revealed the importance 
of liver-produced growth and motility factors, in particular the insulin-like 
growth factors (IGFs). The involvement of this growth factor was then 
demonstrated in vivo through inhibition of IGF signalling pathway. Due to the 
high growth and metastatic propensity of tumor cells, Rag2-/-;γc-/- mice were 
used as model to investigate the metastatic behavior of rhabdomyosarcoma 
cells engineered to improve the differentiation. 
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It has been recently shown that this immunodeficient model can be 
reconstituted with a human immune system through the injection of human 
cord blood progenitor cells. The work illustrated in this thesis revealed that the 
injection of different human progenitor cells (CD34+ or CD133+) showed 
peculiar engraftment and differentiation abilities. Experiments of cell 
vaccination were performed to investigate the functionality of the engrafted 
human immune system and the induction of specific human immune responses. 
Results from such experiments will allow to collect informations about human 
immune responses activated during cell vaccination and to define the best 
reconstitution and experimental conditions to create a humanized model in 
which to study, in a preclinical setting, immunological antitumor strategies.  
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PRECLINICAL MURINE MODELS IN 
BIOMEDICAL RESEARCH 
 
In the last decades progress in biomedical research took advantage from 
the availability of several animal models in which to study complex biological 
processes with a particular attention to human cell and tissue physiology and 
differentiation, tumor growth and metastatic ability. Although mice represent 
the most used experimental mammalian model system, they are separated from 
humans by million years of evolutions. Several species differences in the 
structure and function of the immune system as well as in the metabolism could 
explain why some of the achievements gained in preclinical studies are lost in 
translation (Mestas and Hughes, 2004). Advances in the ability to evaluate 
human processes in preclinical murine models went hand in hand with a 
systematic progression of genetic modification to develop animal models 
transgenic for genes of interest in the pathogenesis of human diseases and 
immunodeficient host mice that could sustain growth of human cells and tissues 
and reproduce the histological features of related pathologies. Here, the 
evolution in preclinical murine model development will be described pointing 
out the main breakthroughs that led to the great progress of the last four 
decades. 
 
MOUSE MODELS IN ONCOGENESIS AND CANCER 
THERAPY 
Models to study human tumor physiology and pathobiology should 
reproduce the most clinically relevant features of human diseases. Their 
usefulness will depend on how close they replicate the initial phases of a human 
disease as well as histopathological features and then progress through the same 
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stages displayed by human pathologies showing similar systemic effects. From 
a molecular point of view, they should involve the same genes and signalling 
pathways detected in human pathology. Furthermore, in these models, drug 
metabolism, kinetics of action and potential side effects should be well 
simulated to assess the efficacy of new therapeutic agents. So far, mouse 
models used in preclinical research have not allowed to overcome the 
morphological and functional differences between mouse and human 
physiology and to accurately study the metabolic modifications of therapeutic 
agents in humans. All these limitations led to a growing need for animal models 
in which to carry out in vivo more accurate translational studies. Two main 
features to define a reliable model can be mentioned. The first is the generation 
of genetically modified murine models expressing oncogenes critical for human 
tumor development. These models have been instrumental in understanding the 
molecular mechanisms involved in tumor initiation but they have been less 
successful in replicating advanced cancers due to differences in transformation 
and progression between human and mouse (Cespedes et al., 2006). On the 
other hand, to overcome these constraints advances have been made in the 
development of immunodeficient murine models to investigate human tumor 
cell growth and metastasis. From the description of the nude phenotype in 1966 
up to the generation of more stable and genetically defined immunodeficient 
phenotypes, huge advances in the study of antitumor approaches have been 
made. The growing efforts to develop reliable murine models led to the 
generation of preclinical models that could more closely sustain human cell 
proliferation, differentiation and physiological functions. These 
immunodeficient murine models lacking both adaptive and innate immunity 
could accept human tumor cell engraftment without the interference of the 
murine immune activity and are useful tools to investigate the function of 
antitumor non-immunological agents. In the following sections the main 
characteristics of the main murine models and research applications will be 
described.  
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Nude mice 
The nude phenotype was firstly described by Flanagan in 1966. The nu 
locus was localized on chromosome 11 and the mutated gene named Hfh11 
(HNF-3/fork head homologue 11), is a member of the Fox gene family 
(Hirasawa et al., 1998). This mutation causes a pleiotropic phenotype: nude 
mice are characterized by loss of hair, thymic agenesis and deficiency of 
mature T lymphocytes. The related immune defects depend on the inability to 
produce cytotoxic helper or suppressor T lymphocytes. Because of the 
inefficient adaptive T compartment, B cell-mediated immune responses are also 
lowered and immunoglobulin (Ig) serum levels are altered (IgG and IgA serum 
levels are greatly reduced, while IgM levels are quite normal compared to 
immunocompetent mice). Since the definition of the immune alteration causing 
this phenotype, nude mice have been used as recipient of human tumor cell 
engraftment, to evaluate human tumor growth and spread and test in vivo the 
efficacy of new therapeutic approaches. However, nude mice show a partial 
immunodeficient phenotype, they still present a functional innate immune 
compartment, a complete natural killer (NK) activity and a partially impaired B 
cell functionality. Both NK and the other cells of the innate immunity 
(macrophages and granulocytes) could inhibit or at least control tumor growth 
and metastasization (Hanna and Burton, 1981; Lozupone et al., 2000). To 
overcome NK-dependent control of tumor cell behavior, nude mice can be 
treated with drugs or antibodies, as for example cyclophosphamide or anti-
asialo GM1 antiserum to reduce NK cell content, prior to cell engraftment. 
However NK depletion is only temporary and not complete in all organs. 
Furthermore, evidences of T cell extrathymic maturation and B cell 
functionality in this mice reveal an unstable and not complete 
immunodepression that could interfere with human tumor growth and 
metastatic spread (Yui et al., 1988; Lake et al., 1991; Orengo et al., 2003). 
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Scid, NOD-scid and NOG mice 
Even though nude mice could successfully sustain the engraftment of 
human tumor cells, normal cells are usually rejected. In 1983, Bosma and 
colleagues described a new mutant strain, with mutation in the Prkdcscid gene 
(protein kinase, DNA activated, catalytic polypeptide; severe combined 
immunodeficiency, abbreviated scid). Due to the mutation in a gene responsible 
for DNA repair, recombination of variable, diversity and joining (VDJ) 
segments necessary for the generation of T- and B-cell receptors is severely 
impaired. The resulting phenotype includes a combined immunodeficiency due 
to the absence of both mature B and T cells besides a strong radiation 
sensitivity due to the genetic defect in genes involved in double-strand break 
repair. However these mice (like nude mice) still present a functional innate 
immune system (NK cells, macrophages and neutrophils). The DNA repair 
defect is not only affecting TCR and immunoglobulin rearrangement but is a 
general defect of all cell types resulting in a relatively high sensitivity to DNA 
damaging agents (i.e., x-irradiation, bleomycin). Furthermore, in addition to the 
gene responsible for scid phenotype, other genes (among which the 
recombinant activating genes, RAG1 and RAG2) are involved in VDJ 
recombination. A consequence of the incomplete block of VDJ recombination 
is that a number of mice show a “leaky” phenotype (i.e., residual T and B 
activity with measurable levels of serum Ig). The leakiness increases with age 
and antigen exposure and virtually all scid mice have detectable T and B cells 
at 1 year of age (Hendrickson, 1993). The availability of scid mice provided an 
alternative model for studying human tumors in vivo. When direct comparisons 
between nude and scid mice have been made, diverse propensities of human 
tumor cell growth and metastasization have been reported (Williams et al., 
1993; Garofalo et al., 1993). Unlike nude mice, scid mice could accept the 
engraftment of hematopoietic cells and still now represent the main murine 
model to study human leukemia cells behavior and treatment strategies. 
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However, levels of engraftment were still low and, due to their high radiation 
susceptibility, scid mice showed a high propensity to develop spontaneous 
tumors and could not be used to test in vivo antitumor agents that act on DNA 
metabolism or have a DNA-damaging activity causing double-strand breaks. To 
overcome the above reported limitations, and abrogate, at least partially, the 
functionality of the innate immune system, different murine strains displaying 
other immunodeficiencies were obtained, e.g. through crossing scid mice with 
non-obese diabetic (NOD) mice.  
NOD mice display several abnormalities in the immune system, which 
cooperate to determine the diabetes susceptibility phenotype (Makino et al., 
1980). The immunodepressed phenotype of NOD mice is caused by at least 
three different mutated genes (located on the so called Idd loci on Chromosome 
3, 9 and 17, but more than 20 loci have been identified even not well 
characterized) important for antigen presentation and T-cell function. The 
resulting immune phenotype is characterized by reduced NK activity and T-cell 
count. Furthermore the innate immunity is impaired due to the absence of 
macrophages and circulating complement. Other immune defects affected the 
differentiation and function of antigen presenting cells (Shultz et al., 1995; 
Anderson and Bluestone, 2005).  
Crossing scid mice with non-obese diabetic (NOD) mice led to the 
generation of NOD-scid mice. NOD-scid mice displayed all immune defects 
illustrated for scid and NOD mice, but unlike NOD mice they did not develop 
diabetes. Unfortunately NOD-scid mice still show a certain degree of radiation 
sensitivity and have a decreased life span (no more than eight months) due to 
the development of thymic lymphomas. Moreover, they still present a residual 
innate immunity activity, and a low but still present NK cell activity. 
Several murine models with defined genotype defects have been 
established acting on genes with a key role in the functionality of the innate 
immune compartment that impedes the successful engraftment of human 
normal and tumor cell lines or tissues (i.e., genes involved in the lysosomal 
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activity, perforin release or β2-microglobulin expression) (Thomsen et al., 
2005; Shultz et al., 2007).  
In 2002 NOD/SCID/γcnull (NOG) murine model was first described (Ito et 
al., 2002). The Interleukin-2 receptor (IL-2R) γ common chain is a crucial 
subunit of hetero di- or trimeric high-affinity receptors for different cytokines 
(IL-2, IL-4, IL-7. IL-9, IL-15 and IL-21), and it is required for signalling 
through these receptors. All these cytokines are responsible for the 
development and homeostasis of B, T and NK lymphocytes. IL-2R γ knockout 
mice are characterized by the absence of functional NK cells, the reduction in B 
and T cell number and show other abnormalities such as very small thymus, 
mesenteric lymph node and spleen due to severe hypoplasia (Cao et al., 1995; 
Di Santo et al., 1995). NOG mice obtained by crossing NOD-scid with γ 
common knockout mice, show no mature B and T lymphocytes and are 
radiation sensitive like NOD-scid mice, but also completely lack NK cells and 
the functionality of the innate immunity is further reduced. Moreover, NOG 
mice do not show the development of spontaneous lymphomas, likely due to 
the lack of cytokine signalling through the IL-2R γ chain and show a normal 
life span (Shultz et al., 2005; Ito et al., 2008).  
 
Rag2-/-;γc-/- mice 
As previously described, RAG genes encode two recombination activating 
proteins, RAG-1 and RAG-2, whose cellular expression is restricted to 
lymphocytes during their developmental stages and is fundamental for the 
development of mature B and T lymphocytes. In 1992, Shinkai and colleagues 
developed a RAG-2-deficient murine model characterized by the absence of 
functional B and T cells, similarly to scid mice (Shinkai et al., 1992). Unlike 
scid mutation, due to the specificity of RAG function and its involvement in the 
initial phases of VDJ rearrangement, the resulting phenotype is completely 
stable and affects only lymphocyte maturation. The deletion of RAG-2 activity 
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caused several alterations in the physiology of the immune system: mice 
showed decreased or occasionally absent thymus, and a reduction of the 
cellularity of other lymphoid organs as spleens and lymph nodes. Crossing of 
RAG-2- and γ common chain-deleted mice led to the generation of a 
completely genotipically defined immunodepressed murine model named Rag2-
/-;γc-/- mice. As previously reported, the common cytokine receptor γ chain is a 
high and median affinity component of the receptors for several cytokines, such 
as IL-2, involved in the activation of T and NK cells and in control of the 
peripheral tolerance, IL-7 responsible for the development and functionality of 
lymphocytes, IL-9 that acts as a growth factor for mast cells, IL-15 involved in 
the regulation of the development and maturation of NK cells and the 
homeostasis of memory lymphocytes, IL-4 and IL-21 that act on 
immunoglobulin production and regulate the isotypic switch. Rag2-/-;γc-/- mice 
show a combined immunodeficiency characterized by the complete absence of 
B, T and NK cells and share all the properties described for NOG mice, with 
the exception that they are completely resistant to radiations (Shultz et al., 
2007).  
Rag2-/-;γc-/- mice and NOG mice represent the most innovative animal 
model for in vivo studies on the development of human immune system. So far 
the best humanization results after engraftment with human hematopoietic cells 
were obtained in these two murine models and more possibilities to study 
human immune responses to immunological approaches are under investigation 
(Manz, 2007; Shultz et al., 2007). A few recent data also support that these 
mice could be more permissive models for in vivo studies on tumor biology and 
therapy (Suemizu et al., 2007; Le Devedec et al., 2009; Bertilaccio et al., 2009). 
 
 15
 16 
 SECTION 1 
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GROWTH AND METASTATIC SPREAD OF 
HUMAN TUMOR CELL LINES IN 
IMMUNODEFICIENT MURINE MODELS 
 
INTRODUCTION 
 
Transplantable models 
One of the main advances in cancer research was the study of human 
tumor cell lines and tissues that could be grown in preclinical models. 
Metastases still remain the most relevant problem in cancer therapy. A 
preclinical murine model should be metastatic, allowing tumor growth and 
spread with a pattern of organ colonization similar to that of the original human 
tumor (Cespedes et al., 2006).  
Transplantable models to study the growth and metastatic behavior of 
tumor cells can be divided into two main groups, syngeneic models or 
xenograft models (Khanna and Hunter, 2005). The former model is referred to 
murine (mouse or rat origin) cancer cell lines that can give rise to tumors once 
implanted in inbred animals with the same genetic background. This type of 
experimental model allows the evaluation of tumor-host interactions that may 
contribute to the metastatic propensity. However, this model system is strictly 
related to murine metabolism and lack many features of human tumors due to 
species-specific differences in oncogenesis. Human-mouse xenograft models 
consist of human cancer cell lines grown in immunocompromised murine hosts. 
In this case, use of immunodeficient mice to prevent immune rejection rules out 
the possibility to examine the role of the immune system in control of tumor 
growth and metastasis. However, human tumor cells can interact with murine 
stromal cells. The residual immune activity of murine models could prevent or 
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reduce human tumor growth and, as mentioned, this constraint led to the 
development of more severely immunocompromised murine models.  
Growth and metastasis of transplantable tumor models, can be studied 
through injection in different anatomical sites. Subcutaneous injection was the 
most used way, but tumors grow in a heterotopic site. The administration in the 
same anatomical location from which the injected tumor was derived is referred 
to as orthotopic delivery. Metastatic ability of transplantable tumors can also be 
tested through direct injection in the systemic circulation; metastases so 
obtained are frequently referred to as experimental metastases. Lateral vein 
injection results primarily in pulmonary metastases, intrasplenic or portal vein 
injection are reliable approaches to induce liver metastases, intracardiac 
injection of cells may result in metastases in a broad panel of sites including 
bone. Other metastatic nodules may be detected resulting from the specific 
interaction between tumor cells and host determinants (i.e., stromal cell 
peculiarity, organ tropism, and specific sensibility to growth or chemotactic 
factors). Experimental metastasis model provide several advantages because of 
generally rapid time of metastasis induction, reproducibility and control of the 
number of injected tumor cells. However, i.v. injected tumor cells skip the early 
steps in the metastatic cascade (i.e., acquisition of a transformed phenotype, 
invasion of the surrounding stroma and extravasation into the hematopoietic 
system). After subcutaneous injection of human tumor cells in xenogeneic 
models, metastases were rarely detected and the heterotopic setting was often 
referred as “non-metastatic” setting. The use of orthotopic injection more 
closely reproduces human cancer behavior including tumor vascularity, 
metastatic organ propensity and responsiveness to chemotherapy (Bibby, 2004; 
Khanna and Hunter, 2005). Interestingly, in some cases changing the injection 
site (orthotopic vs heterotopic site) resulted not only in different growth rates 
and metastasization patterns but also in a differential sensitivity to therapeutic 
agents, revealing the importance of tumor cell-stroma cell interaction in the 
behavior of tumor cells (Wilmanns et al., 1992; Cespedes et al., 2006).  
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Comparative studies of human tumor behavior 
Nude and scid mice have been so far the most used murine models to study 
human tumor behavior. Several studies reported growth of human tumor cell 
lines in these immunodepressed murine models and the detection of metastatic 
dissemination of tumor cells. Comparative studies with different 
immunodepressed mice have been performed. Garofalo and colleagues 
compared the metastatic ability of different tumor histotypes (melanoma, colon, 
ovarian and renal cancer) in nude, scid and beige/nude/xid mice (Garofalo et 
al., 1993). Tumor growth and metastatic ability seemed to correlate not only 
with the severity of the immunodepression of investigated murine models but 
several data revealed that different tumor types showed different propensities 
also linked to intrinsic characteristics of tumor cell lines (Garofalo et al., 1993; 
Welch et al., 1997). The orthotopic implantation of a broad panel of human 
tumor cells of different histotypes in nude mice showed metastatic patterns 
similar to those observed in humans (Cespedes et al., 2006). Nevertheless, the 
innate immune components still present in nude and scid murine models (i.e., 
granulocytes and NK cells) could control human tumor growth and 
metastasization propensity. Scid or NOD-scid mice treated with anti-NK 
antibodies (i.e., GM1 antiserum or TMβ-1) or antibodies to deplete 
granulocytes (i.e., RB6-8C5) showed an increased level in tumor metastasis 
(Lozupone et al., 2000), but higher levels were obtained in more profoundly 
immunodepressed NOG mice (Dewan et al., 2005). Other recent studies in 
NOG mice showed the efficiency of severely immunodepressed murine models 
in allowing human tumor growth leading to a broader and more efficient 
metastasization. Suemizu and colleagues demonstrated the generation of a 
reliable model of liver metastasization of human pancreatic carcinoma in NOG 
mice, while other murine models (namely, nude and scid mice) showed low 
metastatic rates despite the large number of intrasplenic injected cells (Suemizu 
et al., 2007).  
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AIM 
This part of the work aimed at studying the metastatic phenotype and 
mechanism of human sarcoma and other types of human tumor cell lines in the 
severely immunodepressed Rag2-/-;γc-/- mice lacking T, B and NK immunity. 
The possible use of Rag2-/-;γc-/- murine model to evaluate in vivo new antitumor 
and antimetastatic non immunological strategies was also addressed. 
 22 
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RESULTS 
Metastatic spread of human sarcoma cell lines in Rag2-/-;γc-/- mice 
Previous data showed that human rhabdomyosarcomas, osteosarcomas and 
Ewing’s sarcomas cell lines had a poor metastatic ability in nude mice, even 
after the intravenous injection in NK-depleted hosts.  
The metastatic ability of a panel of human musculoskeletal sarcomas was 
tested through intravenous (i.v.) injection in Rag2-/-;γc-/- mice (Table 1). Nude 
mice with NK depletion obtained through anti-asialo GM1 antiserum were also 
used as control model. Human sarcoma cell lines comprised osteosarcoma 
(Saos-2 and U2OS), Ewing’s sarcoma (TC-71 and 6647), and 
rhabdomyosarcoma (the alveolar rhabdomyosarcoma cell line SJ-Rh4 and two 
clones derived from the RD embryonal rhabdomyosarcoma cell line, RD/12 
and RD/18).  
In a first set of experiments mice received the intravenous injection of 2 x 
106 human tumor cells. Several sarcoma cell lines showed a 100% incidence of 
lung metastases (Saos-2, U2-OS, TC-71, 6647 and RD/18) in Rag2-/-;γc-/- mice 
with a significant increase in the median number of metastases compared to 
nude mice (Table 1). Furthermore, the metastatic growth was faster in Rag2-/-
;γc-/- than in nude mice as evidenced by the earlier median time to sacrifice in 
the double knockout host compared to nude mice (Table 1). Interestingly, most 
sarcoma cell lines (Saos-2, TC-71, 6647, SJ-RH4, RD/12 and RD/18) showed a 
very high metastatic colonization of the liver in Rag2-/-;γc-/- mice, while 
completely failed to colonize the liver of nude mice (Table 1). 
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Table 1. Metastatic capacity of human sarcoma cells in immunodepressed mice 
Lung metastases Liver metastases Other metastatic sites 
Incidence  Median Range    Incidence  Median Range    Incidence  Median  Range Cell line 
i.v. cell 
dose 
Mice 
Median 
time to 
sacrifice 
(days)     %             %             %       
       2x106 Rag2/γc‐KO  68  4/4   100  >200*  >200‐>200 4/4*  100  >200*  >200‐>200 4/4*  100  3*  1‐32
2x106 Rag2/γc‐KO  48  5/5# 100  >200*  >200‐>200       
       
               
5/5*  100  7*  2‐17 0/5  0  0    0‐0 Saos‐2 
2x106 nude1 89  8/19  42  0    0‐161 0/19  0  0    0‐0 0/19  0  0    0‐0 
                   
2x106 Rag2/γc‐KO  36  9/9  100   >200*  >200‐>200       
       
               
0/9  0  0    0‐0 0/9  0  0    0‐0 
U2‐OS 
2x106 nude1 63  17/20  85  41    0‐>200 0/20  0  0    0‐0 0/20  0  0    0‐0 
                   
2x106 Rag2/γc‐KO  30  12/12*  100  37*  1‐105       
       
                   
12/12*  100  >200*  >200‐>200 8/12  67  1    0‐62
TC‐71 
2x106 nude1 78  8/24  33  0    0‐10 0/24  0  0    0‐0 16/24  67  1    0‐32
               
2x106 Rag2/γc‐KO  21  5/5  100  114*  18‐157       
       
               
5/5*  100   >200*  >200‐>200 5/5  100  21*  13‐292
6647 
2x106 nude1 54  13/20  65  5    0‐67 0/20  0  0    0‐0 18/20  90  3    0‐162
                   
2x106 Rag2/γc‐KO  59  1/5  20  0    0‐4       
       
       
               
5/5  100  >200    >200‐>200 2/5  40  0    0‐22
2x106 Rag2/γc‐KO  35  0/11  0  0    0‐0 11/11  100  40    14‐113 4/11  36  0    0‐22SJ‐RH4 
2x106 nude1   n.d.      n.d.      n.d.       
                   
2x106 Rag2/gc‐KO  79  11/14*  79  3*  0‐17       
       
               
14/14*  100  75*  25‐218 10/14*  71  2*  0‐32
RD/12 
2x106 nude1 97  6/19  32  0    0‐8 0/19  0  0    0‐0 0/19  0  0    0‐0 
                   
2x106 Rag2/γc‐KO  36  15/15  100  >200*  112‐>200    15/15*  100  >200*  >200‐>200   
        
15/15  100  6*  4‐572
RD/18 
2x106 nude1 58  14/15  93  26    0‐327 0/15  0  0    0‐0   15/15  100  2    1‐82
 
Rag2−/−;γc−/− and nude mice received the intravenous injection of 2x106 sarcoma tumor cells. 1Pretreated with anti-NK antibodies (see Materials and methods).  
2Metastatic sites: Saos-2: kidneys, adrenals, lymphoid organs; TC-71: kidneys, adrenals, bone, ovary; 6647:  kidneys, adrenals, ovary, brown fat, lymphoid organs; SJ-Rh4: 
kidneys; RD/12: kidneys, adrenals, ovary; RD/18: kidneys, adrenals, ovary, lymphoid organs. Rag2−/−;γc −/− indicated as Rag2/γc-KO. n.d.=not done.  
Significance of difference versus nude mice: # p<0.05, * p<0.01 (χ2 test for frequency, nonparametric Mann-Whitney rank sum test for metastasis number). 
Liver metastases were the result of organ-selective homing of individual tumor 
cell lines, independent of the ability to colonize the lungs or other organs (Table 
1 and Figure 1). As graphically reported in Figure 1, different sarcoma cell 
lines showed diverse organ-specific metastatic propensities for liver and lung 
colonization. Furthermore, several cell lines showed a metastatic propensity to 
colonize organs other than lungs and liver significantly enhanced in Rag2-/-;γc-/- 
mice (see data for two rhabdomyosarcoma, RD/12 and RD/18 and Ewing’s 
sarcoma, 6647 or osteosarcoma cell lines Saos-2 in Table 1). Metastatic sites 
were mainly kidneys, adrenal glands and lymphoid organs (see Table 1 for 
details). Multi-organ metastatic pattern was also observed after injection of 
decreasing cell numbers (data not shown).  
These results indicated that Rag2-/-;γc-/- mice were a more permissive host 
to study the metastatic behavior of human cell lines. 
 
 
 
 
 
 
 
 
 
 
 
SJ-Rh4 SAOS-2 U2OS 
Lungs 
Liver 
 
Figure 1. Organ-specific metastatic capacity of human sarcoma cells injected i.v. 
in Rag2−/−;γc−/− mice. Lungs (above, filled with black India ink to better identify and 
quantify metastases) and liver (below) of mice which had received the i.v. injection of 
indicated human sarcoma cells. 
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Imaging of Ewing’s sarcoma metastasis 
Ewing’s sarcoma in humans usually show a strong tendency to metastasize 
to lungs and bones. TC-71 Ewing’s sarcoma cell line is able to give rise to bone 
metastases in nude mice (Scotlandi et al., 2000). Because of the early sacrifice 
time due to liver colonization, in Rag2-/-;γc-/- mice, bone metastases were hardly 
detectable. To obtain a more sensitive detection of metastases, TC-71 cells 
were transfected with pEGFPN1 plasmid to stably express Enhanced Green 
Fluorescent protein (EGFP). As illustrated in Figure 2, through fluorescent 
imaging, metastases to ovary and bones were observed, thus confirming that 
Ewing’s sarcoma cells maintain such tropism in Rag2-/-;γc-/- mice.  
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Figure 2. Organ-specific metastatic ability of human Ewing’s sarcoma cells 
injected i.v. in Rag2−/−;γc −/− mice. TC-71 EGFP cells were i.v. injected in Rag2-/-;γc-/- 
mice and metastases were localized with a fluorescent imaging device (see Materials 
and Methods for details). 1: liver metastases, 2: mandible metastases, 3: femur 
metastases; 4: ovary metastases. 
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Tumorigenicity and spontaneous metastases in Rag2-/-;γc-/-
Rag2-/-;γc-/- mice showed the appearance of spontaneous metastases after 
the subcutaneous (s.c.) injection of human osteosarcoma (U2-OS) and Ewing’s 
sarcoma (TC-71) cell lines (Table 2). The s.c injection of a lower amount of 
tumor cells in Rag2-/-;γc-/- mice than in nude mice is sufficient to allow the local 
growth of tumor and the induction of spontaneous metastases to the lungs. 
Rag2-/-;γc-/- mice showed a faster tumor growth than nude mice, and 
interestingly, at the time of sacrifice, metastases in organs other than lungs were 
detectable in both investigated human sarcoma cell lines (Table 2). 
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Table 2. Tumorigenicity and induction of spontaneous metastasis of human sarcoma cells 
  Tumorigenicity Lung metastases Liver metastases Other metastatic sites 
Incidence Incidence Median Range  Incidence Median Range Incidence Median Range 
Cell 
line 
s.c. 
cell 
dose 
Mice 
Median 
time to 
sacrifice 
(days) 
                      
                                 
  % 
Median 
latency 
(days)    %     %       %  
       
10x106 Rag2/γc‐KO  78     
           
                   
  5/5 100 31 5/5  100 >200*  >200‐>200   2/5 40 0   0‐1       4/5# 80 3#   0‐41
U2‐OS 
30x106 Nude  118 4/5 80
 
33 2/5 
 
40
 
0    0‐45 0/5 0 0   0‐0       0/5 
 
0
 
0    0‐0  
         
2x106 Rag2/γc‐KO  27         
         
     
  5/5 100 10 3/5  60 3    0‐14 0/5 0 0   0‐0       3/5  60 1    0‐11
TC‐71 
3x106 Nude  42   5/5 100 8 0/5 
 
0
 
0    0‐0 0/5 0 0   0‐0       0/5  0 0    0‐0  
                                                   
 
1Metastatic sites: U2-OS: kidneys, adrenals, peritoneum; TC-71: lymph nodes. 
Rag2−/−;γc −/− mice are indicated as Rag2/γc-KO. 
Significance of difference versus nude mice: # p<0.05, * p<0.01 (χ2 test for frequency, nonparametric Mann-Whitney rank sum test for metastasis 
number) 
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Metastatic ability of human carcinoma cell lines in Rag2-/-;γc-/- 
mice 
To investigate whether the high metastatic ability and mostly the liver 
metastatic colonization observed in Rag2-/-;γc-/- mice were a peculiar 
characteristic of the investigated sarcoma cell lines or a general feature of all 
types of human tumors, a panel of carcinoma cell lines of diverse histologic 
origin (liver, colorectal, breast, or ovary) was studied. Data obtained after the 
i.v. injection of 2 x 106 cells, in analogy with the experiments of sarcoma 
metastasization, are reported in Table 3. All investigated human carcinomas 
were completely unable to metastasize to the liver of Rag2-/-;γc-/- mice (Table 
3), irrespective of their ability to colonize the lungs or other mouse organs. 
Liver carcinoma cells (Hep-G2) were able to metastasize to different lymphoid 
organs, adrenal glands, kidney and urogenital system. Ovary carcinoma cells 
(SK-OV-3) and the colon adenocarcinoma cell line HT-29 showed essentially 
only lung metastases (Table 3). A comparison of metastatic spread obtained in 
Rag2-/-;γc-/- and nude mice was made with SK-OV-3 cells, confirming that 
Rag2-/-;γc-/- mice allow a better detection of metastatic ability (Table 3).
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Table 3. Metastatic capacity of human carcinoma cells in Rag2−/−;γc−/− mice 
Lung metastases Liver metastases Other metastatic sites 
Incidence Median Range     Incidence Median Range   Incidence Median Range 
Cell line
i.v. cell 
dose 
Mice 
Median 
time to 
sacrifice 
(days)     %             %             %       
       HepG2  2x106 Rag2/γc‐KO  43  0/5  0 0  0‐0 0/5  0 0  0‐0 5/5 100 6  4‐112
                                  
Caco‐2  2x106 Rag2/γc‐KO  97  0/4  0 0  0‐0       
                       
0/4  0 0  0‐0 0/4 0 0  0‐0 
           
HT‐29  2x106 Rag2/γc‐KO  19  5/5  100 >200  >200‐>200       
                       
0/5  0 0  0‐0 0/5 0 0  0‐0 
           
MCF7  2x106 Rag2/γc‐KO  97  1/4  25 0  0‐1       
                       
0/4  0 0  0‐0 0/4 0 0  0‐0 
           
2x106 Rag2/γc‐KO  37  3/3  100 >200  >200‐>200       
       
0/3  0 0  0‐0 0/3 0 0  0‐0 
SK‐OV‐3
2x106 nude1 61  4/4  100 32  5‐>200 0/4  0 0  0‐0 0/4 0 0  0‐0 
 
1Pretreated with anti-NK antibodies (see Materials and methods).  
2Metastatic sites: kidneys, adrenals, urogenital system, lymphoid organs.  
Rag2−/−;γc−/− mice are indicated as Rag2/γc-KO..
In vitro analysis of molecular mechanisms involved in metastatic 
growth 
Liver metastatic localizations observed in Rag2-/-;γc-/- mice, specific of 
most sarcoma cell lines, and the high rate of metastatic growth in this organ, 
could be due to the presence in liver of factors able to induce proliferation or 
chemotaxis of sarcoma cells. As a model of interaction with liver 
microenvironment, tumor cells were exposed to the culture supernatant of a 
liver-derived human hepatoma cell line (HepG2 cells). Figure 3 shows that the 
growth of sarcoma cell lines (with the exception of U2-OS cells which were not 
able to colonize the liver) was stimulated by HepG2 conditioned medium. For 
these sarcoma cell lines, the growth ability in conditioned medium was 
significantly increased compared with the growth observed in normal medium. 
Growth of carcinoma cells, which did not show any hepatic metastasization 
propensity, was not modified by conditioned medium (Figure 3). 
A key mechanism relevant for metastatic spread and organ-selective 
colonization is the ability of tumor cells to respond to chemotactic stimuli. 
Experiments to evaluate the migratory propensity of sarcoma cells in medium 
conditioned by hepatic cells compared to normal medium were performed. 
Each sarcoma cell line showed a different intrinsic basal migratory capacity 
(Figure 4A). After exposure to HepG2 conditioned medium, the migratory 
ability was stimulated in same sarcoma cell lines (Saos-2 and RD/12 showed a 
significant increase in the number of migrated cells) (Figure 4A). SJ-Rh4 and 
RD/18 cell lines (whose growth was stimulated by HepG2 supernatants) 
showed a very low basal migratory propensity that was not stimulated by 
conditioned medium. Similar migratory patterns were obtained after exposure 
of sarcoma cells to medium conditioned by mouse liver progenitor cells 
(MLP29.1C cell line) (data not shown). Carcinoma cells did not show any 
migratory ability both in normal and conditioned medium (Figure 4A).  
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Figure 3. In vitro growth of human sarcoma and carcinoma cells exposed to 
medium conditioned by human liver-derived cells (HepG2). 104 cells were seeded 
in 96 well plates in normal or conditioned medium. Cell growth was evaluated after 48 
hours of culture through the WST-1 test (see Materials and Methods for details). Data 
are means of at least two independent experiments. Stars indicate a statistically 
significant difference between normal and conditioned medium (p<0.05 at least, 
Student’s t test). 
 
 
The liver produces a wealth of growth factors that could attract tumor cells 
and make them proliferate, which could be one of the reasons why it is a 
frequent site of metastatic spread in Rag2-/-;γc-/- mice. One logical link between 
the liver and sarcomas is the insulin-like growth factor (IGF) axis. The liver is 
the major producer of IGFs in the body (Miyamoto et al., 2005; Rikhof et al., 
2009). Several studies demonstrated that human sarcoma tissues and cell lines 
express type 1 IGF receptor (IGF1R) which mediates responses to both IGF1 
and IGF2 and underline the involvement of related signalling circuits in human 
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sarcoma cell growth, in particular rhabdomyosarcomas and Ewing’s sarcomas, 
in a paracrine and/or autocrine manner (Scotlandi and Picci 2008; Rikhof et al., 
2009). 
 
 
Sa
os
-2
U
2O
S
TC
-7
1
66
47
SJ
-R
h4
R
D
/1
2
R
D
/1
8
H
T-
29
M
C
F-
7
SK
-O
V-
3
0
2500
5000
7500
10000 Medium
Conditioned
?
?
M
ig
ra
te
d 
ce
lls
Saos-2 RD/12
0
25
50
Medium+α-IGF1R
Conditioned+α-IGF1R
?
?
n.s.
n.s.
In
hi
bi
tio
n 
of
 m
ig
ra
tio
n 
(%
)
A
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Migration of human sarcoma cells in conditioned medium. A: Migration 
assay. Star indicates a significant difference between normal and conditioned medium 
(p<0.05 at least, Student’s t test). B: Percentage of reduction of liver-stimulated or 
basal migration caused by IGF1R neutralization. Star or n.s. indicate a significant or 
not significant difference of cell migration versus cell migration in the corresponding 
medium in the absence of anti-IGF1R, respectively (star = p<0.05 at least, Student’s t 
test; n.s. = not significant). 
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To evaluate the involvement of IGFs in the chemotactic behavior induced 
by HepG2 conditioned medium in sarcoma cells, migration experiments were 
performed in which a blocking monoclonal antibody against IGF1R was added 
to the conditioned or not conditioned medium. Figure 4B shows that the 
blocking of IGF1R reduced by half the chemotactic activity of HepG2 
conditioned medium, thus demonstrating a significant contribution of 
hepatocyte-derived IGFs in sarcoma migration ability. 
 
 
Therapy of liver metastasis by dual PI3K-mTOR inhibitor 
The broad liver metastasization of human sarcoma cell lines in Rag2-/-;γc-/- 
mice will allow the employment of this murine model to study new non-
immunological antimetastatic approaches. In particular, the involvement of the 
IGF axis in the liver tropism of human sarcoma cells suggests that therapeutic 
agents targeting IGF1R or downstream signal transducers could have a specific 
antimetastatic effect in this system. To test this hypothesis, Rag2-/-;γc-/- mice 
received the i.v. injection of the rhabdomyosarcoma cell line RD/18 to induce 
liver micrometastases. The day after and for a total of 18 administrations, tumor 
cell injected mice received the treatment with the dual PI3K/mTOR kinase 
inhibitor NVP-BEZ235 (Serra et al., 2008). As clearly illustrated in Figure 5A, 
mice treated with NVP-BEZ 235 showed a striking reduction in the liver 
metastatic burden. The liver weight of treated mice reached values similar to 
those of naïve Rag2-/-;γc-/- mice, due to a statistically significant reduction of 
the metastatic load (Figure 5B). The numbers of metastases in lungs and other 
sites were also significantly decreased (Figure 5B). This result illustrated the 
experimental reliability of Rag2-/-;γc-/- mice model to test the metastatic ability 
of human tumor cells. 
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Figure 5. Therapy by NVP-BEZ235 of liver metastases induced by the i.v. 
injection of human RD/18 rhabdomyosarcoma cells in Rag2-/-;γc-/- mice. A: liver 
metastatic burden in untreated mice (above) or in mice treated with NVP-BEZ235 
(below). B: Quantitative evaluation of metastatic load to liver (left), lungs (middle), 
and other sites (right). Mean and standard error of the mean (SEM) from 5 mice is 
shown for each group. Star indicates a statistically significant difference (p<0.05, 
Student’s t test). Liver weight in normal Rag2−/−;γc−/− mice was 1133 ± 30 mg. 
 
 
 
The results reported above have been included in a paper accepted for 
publication (Nanni et al., Eur J Cancer 2009 Dec 21 E-pub). 
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Metastatic behavior of rhabdomyosarcoma cells engineered to 
improve myogenic differentiation 
Due to high tumor growth and metastatic spread of sarcoma cells in this 
model, Rag2-/-;γc-/- mice were used as murine model to test in vivo the 
therapeutic efficacy of a gene therapy approach. Rhabdomyosarcoma cell 
populations revealed a considerable differentiative heterogeneity, containing a 
variable proportion of cells at different stages of differenziation. The overall 
proliferative and tumorigenic capacity of rhabdomyosarcomas is inversely 
related to the degree of myogenic differentiation (Lollini et al., 1991; Merlino 
and Helman, 1999). Myogenin (Myog) is one of the member of the myogenic 
regulatory factors that coordinate gene expression and drive terminal muscle 
differentiation (De Giovanni et al., 2009) characterized by the expression of 
myosin and other contractile proteins. RD/12 cells show a very low expression 
of myogenin and a low differentiation capability. Preliminary in vitro 
experiments, showed that the forced expression of Myog gene in RD/12 cells 
(RD/12-Myog cells) led to an overall increased myosin production, to the 
appearance of a fraction of multinuclear myotube-like elements and decreased 
the migratory capacity (Astolfi et al., 2001 and data not shown).  
The therapeutic implication of the forced Myog expression was analyzed 
both in experiments of tumor growth and in experiments of metastatic ability 
after i.v. injection in nude and Rag2-/-;γc-/- mice. The tumorigenicity of RD/12-
Myog cells in nude mice was strongly impaired with respect to RD/12 or 
RD/12 cells transduced with an empty plasmid (RD/12-Neo cells) (data not 
shown). Studies of induction of experimental metastasization in nude mice 
revealed that only 35% of mice were affected by lung nodules after the 
injection of both RD/12 or RD/12-Myog cells. As reported above, Rag2-/-;γc-/- 
mice injected with RD/12 cells showed both lung and liver colonization (Table 
1 and Table 4). When i.v. injected in Rag2-/-;γc-/- mice, RD/12-Myog cells gave 
a reduced liver metastatic load compared to RD/12 or RD/12-Neo cells (Table 4 
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and Figure 6). This experiment confirms the translational potential of  
Rag2-/-;γc-/- mice as an efficient murine model to investigate the behavior of 
human tumor cell lines and to evaluate antitumor approaches. 
 
 
 
Table 4. Metastatic spread of myogenin-transduced human 
rhabdomyosarcoma cells in Rag2-/-;γc-/- mice. 
Cells  Lung 
metastasis 
Liver 
metastasis 
  Incidence  Median  Range  Incidence  Median  Range 
RD/12  3/5 (60%)  2  0‐17  5/5 (100%)  125  74‐218 
RD/12‐Neo2  3/4 (75%)  2  0‐2  4/4 (100%)  134  109‐29 
RD/12‐Myog1  4/5 (80%)  2  0‐31  5/5 (100%)  30*  23‐36 
RD/12‐Myog2  2/4 (50%)  1  0‐1  4/4 (100%)  60*  32‐89 
 
Rag2-/-;γc-/- mice received the i.v. injection of 2 x 106 cells and were sacrificed 10 weeks later.  
* indicates a significant difference versus RD/12 and RD/12-Neo2 (p<0.05, Wilcoxon rank sum 
test). 
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Figure 6. Metastatic spread of RD/12 and RD/12-Myog cells to the liver of 
Rag2−/−;γc−/− mice. Three representative fixed and dissected livers of Rag2-/-;γc-/- mice 
injected with RD/12 (above) or transduced RD/12-Myog (below) cells are shown. 
Metastasis counts are shown in Table 4. 
 
 
 
The results reported above have already been published (Nanni et al., 
2009). 
 38 
DISCUSSION 
The metastatic spread and growth of malignant tumors from the primary 
site is still the most relevant problem in the field of tumor therapy. The study of 
metastasis biology of different tumor types will help in improving treatment 
outcome of patients. In vivo models to study the biological complexity of 
human tumor metastasis are based on immunodepressed mice.  
In this thesis, the metastatic ability of different human sarcoma cell lines 
was tested in a new double knockout immunodeficient murine model, Rag2-/-
;γc-/- mice, compared to nude mice. The metastatic potential of human sarcomas 
was higher in Rag2-/-;γc-/- mice than in nude mice in terms of both metastatic 
sites and metastasis number: in Rag2-/-;γc-/- mice a strong increase of metastatic 
ability to lungs, liver and other sites was observed. Furthermore, the metastatic 
growth in Rag2-/-;γc-/- mice was faster than in nude mice, thus allowing an 
earlier metastasis evaluation. The different metastatic ability shown by human 
tumor cells in the two murine hosts enlightens the importance of the residual 
host immune response and of the host-tumor interaction in the metastatic 
spread. Rag2-/-;γc-/- mice completely lack cells of the adaptive immune system 
(B ad T cells), and NK cells, due to the deficiency of IL-2R γ-chain causing an 
impaired signalling efficiency of multiple cytokine receptors. The relative 
inefficiency of metastatic spread of human cell lines in nude mice could be 
attributed mainly to their NK activity, which efficiently kills circulating tumor 
cells thus contributing to the metastatic control in various organs (Budzynski et 
Radzikowski, 1994; Volpe et al, 1999; Wiltrout, 2000, Dewan et al., 2005). 
Routine pretreatment of nude mice with anti-NK antibodies, as was done here, 
improved metastatic spread of human tumors, but with limitations as for 
example the transient effect of NK depletion, and the impossibility to determine 
to which degree diverse parenchymatous NK populations were depleted.  
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Severely immunodepressed mice could provide a more favorable 
environment to determine tumor cell spontaneous metastatic propensity. A 
recent work described NOG mice as a quantitative model of pancreatic 
carcinoma metastasis (Suemizu et al., 2007) while in reports published in the 
last year, while our studies were ongoing, Rag2-/-;γc-/- mice were investigated as 
hosts to study murine tumor and human leukemia cell behavior or to investigate 
molecular mechanisms that driven Ewing sarcoma growth in vivo (Le Devedec 
et al., 2009; Bertilaccio et al., 2009; Richter et al., 2009).  
In this study, we showed that the combined immunodeficiency of T and B 
cells caused by Rag2 knockout, coupled with the NK deficit mediated by the 
absence of the γc interleukin receptor chain, gives rise to a superior host model 
for metastasis studies of human sarcomas with an impressive multi-organ 
metastasization both after i.v. and s.c. injection.  
Besides NK control of tumor metastasization, this study enlightens another 
important topic related to tumor cell behavior, i.e. the presence of 
microenvironmental factors that could specifically influence sarcomas spread 
and metastasis growth in the liver. 
In addition to the quantitative differences in the metastatic ability, human 
sarcoma cells showed a different metastatic organ-tropism in the two murine 
models. In particular, human sarcomas displayed a strong liver tropism in  
Rag2-/-;γc-/-mice mainly after the experimental induction of metastases. In 
humans, liver tropism of sarcomas is a rare feature and mostly depends on the 
anatomical location of the primary tumor (Jaques et al., 1995; Pawlik et al., 
2006) but recent advancement in the local tumor control led to a modified 
sarcoma metastatic pattern with an increase in liver secondaries (Giuliano et al., 
1984). Worth of interest, the ability of visceral sarcomas to reach the liver, 
probably due to the absence of NK control, could be ascribed to a novel 
immune escape mechanism which could in turn lead to immunotherapeutic 
strategies to specifically potentiate local NK activity in visceral sarcomas.  
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On the other side, not all tested tumor cell lines gave origin to liver 
metastatic nodules, so that the phenomenon can be ascribed not just to the 
complete absence of NK cells which control circulating tumor cells. Liver 
tropism was the result of a tumor-specific peculiarity, because it was restricted 
to human sarcomas, whereas carcinomas did not colonize the liver of  
Rag2-/-;γc-/- mice. The issue was to analyze why sarcomas and not carcinomas, 
which are known to metastasize the liver of cancer patients, showed this 
massive hepatic spread in Rag2-/-;γc-/- mice. It could be hypothesized that the 
diverse immune components in the two murine models could affect both 
positively and negatively the metastatic liver-tropism. First, carcinoma cell 
lines could be more sensitive than sarcomas to residual immune components of 
Rag2-/-;γc-/- mice, in particular liver Kuppfer cells that play an important role in 
removing tumor cells through phagocytosis and production of pro-
inflammatory cytokines following tumor antigen stimulation (De Blaser et al., 
1994; Philips, 1989). If this is the case, then treatments that selectively impair 
liver phagocytosis could enhance liver metastasis of human carcinomas (van 
der Bij et al., 2005). A specular hypothesis would be that Rag2-/-;γc-/- mice lack 
immune components able to promote liver metastasization by human 
carcinomas, like for example IL-10 that acts as a major factor in liver metastatic 
propensity of colorectal carcinomas (Jessup et al., 2004). This cytokine is 
physiologically produced by various cell types missing in knockout Rag2-/-;γc-/- 
mice, like activated T helper, B and NK cells. A further issue that could 
influence tumor-host interaction lay in the species-specificity of ligands and 
receptor pairs required for tumor cell adhesion, migration or proliferation. For 
instance the human carcinoembryonic antigen (CEA) system is evolutionarily 
different from the murine equivalent (Kuespert et al., 2006), and it is known 
that CEA expression can enhance the metastatic potential of human colorectal 
carcinomas as demonstrated by Jessup and colleagues (2004). To investigate 
these hypotheses, the viability of further “humanized” murine model transgenic 
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for human genes involved in cancer metastasization could be useful to produce 
suitable model in which to study human tumor cells biology and metastatic 
colonization. 
The frequent but specific liver colonization and the fast metastatic growth 
of human sarcomas in this organ suggested the presence of microenvironmental 
molecular determinants acting as growth factors or chemotactic agents. Only 
the subset of sarcoma cells able to colonize the liver of Rag2-/-;γc-/- mice 
showed growth and chemotactic response to HepG2 conditioned medium. The 
fact that liver metastatic and non-metastatic cells could be discriminated in 
vitro confirmed that the different behavior observed in vivo is a cell-
autonomous phenotype. 
The liver is the major bodily producer of IGF1 and IGF2 (Rikhof et al., 
2009), and in low quantity of other factors as EGF, HGF, TGF- β, PDGF, 
VEGF that could express a key role in the metastatic spread (Miyamoto et al., 
2005; Kmiec, 2001). 
In search of molecules mediating the observed effects, IGFs appeared as a 
logical candidate because of sarcoma cell expression of IGF1R inducing cell 
proliferation and chemotaxis (Scotlandi and Picci, 2008; Rikhof et al., 2009). 
Chemotaxis experiments performed blocking the IGF1R axis confirmed the 
importance of its signalling in this experimental system. Even if the IGF1R 
blocking antibody significantly reduced the effect of liver supernatant, this 
activity was not completely abolished, thus indicating the involvement of 
additional mediators playing a key role, as could be expected given the 
complex metabolic function of the liver (Kmiec, 2001). Several studies 
demonstrated that the hepatocyte growth factor/scatter factor (HGF/SF) is 
involved in sarcoma invasive phenotype acting as a paracrine and autocrine 
growth and migration factor for human musculo-skeletal sarcomas (Ferracini et 
al., 1995; Ferracini et al., 1996). In particular, the rhabdomyosarcoma cell line 
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RD/18, that did show an increased growth ability in HepG2 supernatant but no 
migratory response, were chemoattracted by HGF (Ferracini et al., 1996).  
Using immunodepressed Rag2-/-;γc-/- mice it could be shown the 
cooperation of immune system counterpart (NK cells) and organ specific 
mediators (IGFs, and eventually other microenvironmental signals) in 
determining the metastatic potential of human sarcoma cells. 
Rag2-/-;γc-/- mice were successfully used in in vivo experiments to verify 
the antimetastatic ability of non-immunological approaches targeting specific 
factors involved in sarcoma cells metastatic propensity (IGF axis) and tumor 
cell differentiation ability (forced expression of Myog gene in sarcoma 
undifferentiated cells). The identification of IGFs as important factors of  liver 
metastasization of human sarcomas suggested that agents specifically targeting 
the IGF axis or downstream signal transducers (Scotlandi and Picci, 2008) 
could be effective therapeutic antimetastatic approaches. The experiment of 
therapy of liver metastases in Rag2-/-;γc-/- mice demonstrated that the dual 
PI3K/mTOR kinase inhibitor NVP-BEZ235 (Serra et al., 2008) strongly 
decreased metastatic burden to liver, lung and other metastatic sites.  
Due to the high growth propensity of tumor cells, Rag2-/-;γc-/- mice are a 
suitable model to better study the metastatic potential of RD/12 
rhabdomyosarcoma cells compared to RD/12-Myogenin transduced cells. 
While nude mice did not allow a good comparison due to the low metastatic 
propensity of RD/12 control or treated cells, the new immunodepressed murine 
model clearly showed the therapeutic efficacy of the engineered differentiative 
behavior in RD/12 cells.  
These results showed that Rag2-/-;γc-/- mice are a powerful model to verify 
the biological and malignant characteristics of human tumor cells and to test 
antimetastatic targeted therapy.  
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 SECTION 2 
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 46 
Rag2-/-;γc-/- MICE AS A PRECLINICAL MODEL OF 
HUMAN ANTITUMOR IMMUNE RESPONSES  
 
INTRODUCTION 
 
Humanized mice models 
Since the late 1980s, the development of humanized preclinical mouse 
models has been pursued to study the function and development of the human 
immune system. Humanized mice comprise normal, immunocompetent murine 
models transgenic for human genes (i.e., HLA or human immunoglobulins) or 
immunodeficient mice in which human tissues, hematopoietic stem cells (HSC) 
or mature peripheral-blood mononuclear cells (PBMC) have been adoptively 
transferred (Thomsen et al., 2005; Shultz et al., 2007). This second group of 
preclinical models is also defined as mouse-human chimaeras in which the 
function of the immune compartment is driven by human cells that proliferate, 
differentiate, and/or exhibit their physiological function within the murine host. 
Since the first reports of successful transfer of normal human peripheral blood 
leukocytes in scid mice (Bosma et al., 1983; Moseir et al., 1988) this approach 
has been widely applied to perform analysis of human immune function. In the 
last few years, new and more severely immunocompromised murine models 
(most notably, NOG and Rag2-/-;γc-/- double knockout mice) were obtained and 
used in many areas of immunology, including the investigation of the ontogeny 
and differentiation of human immune cells, of autoimmunity mechanisms, of  
long-term immunological memory, of in vivo interactions between viruses and 
the immune system to define new vaccine strategies and of anticancer 
immunotherapies (Shultz et al., 2007, Zhang et al., 2008). 
So far, evidences of human immune activation in humanized Rag2-/-;γc-/- 
mice were obtained after stimulation with viral antigens such as Human 
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Immunodeficiency Virus (HIV) type 1, Epstein-Barr Virus (EBV), or Herpes 
Simplex Virus type 2 (Gorantla et al., 2007; Traggiai et al., 2004; Strowig et al., 
2009; Kwant-Mitchell et al., 2009a) or with tetanus toxoid (Traggiai et al., 
2004). The first evidences of human immune activation were obtained through 
the detection of specific human IgG, even if detected levels were low and not 
present in all treated mice.  
Very few data described the application of humanized mice to study 
strategies to induce effective anti-tumor human immune responses. In a very 
recent work, Strowig and colleagues demonstrated the activation of T cell 
responses and interferon (IFN)-γ production in mice infected with EBV 
(Strowig et al., 2009). The activation of immune system in these mice was able 
to protect from the development of EBV-induced tumors even though, in this 
experimental setting, researchers were unable to detect the induction of specific 
anti-EBV immunoglobulins. Kwant-Mitchell and colleagues demonstrated the 
activation of human natural killer cells and their ability to produce IFN-γ after 
stimulation with human cytokines and to partially control the growth of human 
leukemia cells (Kwant-Mitchell et al., 2009b). These are the first promising 
reports of a partially functional human immune system able to protect from 
tumor development, but strategies to achieve a fully functional adaptive 
immune response to study immunological antitumor approaches are still under 
investigation. 
 
Definition and source of human progenitor cells 
In humans, hematopoietic stem cells (HCS) can be commonly collected 
from three different tissues: bone marrow, peripheral blood or umbilical cord 
blood. Bone marrow is the classical source of hematopoietic progenitor cells 
where they represent <1% of the total population. A very small number of HSC 
and progenitor cells circulate in the bloodstream but they can be mobilized 
from bone marrow after treatment with cytokines such as granulocytes-colony 
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stimulating factor. Blood from the umbilical cord blood is a very rich source of 
human progenitor cells and at present, represent a very popular source of 
human progenitor cells for research purposes. Other sources of HSC are 
represented by human fetal tissues and some examples of reconstitution with 
thymic or fetal liver tissues or cells purified from these sources are reported 
(Holyoake et al., 1999; Lan et al., 2006; Shultz et al., 2007).  
Many studies of reconstitution of a human immune system were performed 
with hematopoietic progenitor cells sorted for CD34 positivity. CD34 is a 
glycosylated surface antigen that regulates hematopoietic cell adhesion to 
stromal cells and signal transduction of other hematopoiesis-related genes 
(Holyoake and Alcorn, 1994). Human CD34+ progenitor cells transplanted into 
subletally irradiated newborn or adult NOD-scid, NOG or Rag2-/-;γc-/- mice led 
to the development of human CD45+ leukocytes and to differentiation of all 
major cell populations of the human hemato-lymphoid system was observed in 
transplanted mice, including dendritic cells, T cells and natural-interferon-
producing cells, B cells and immunoglobulin-producing cells and to a lesser 
extent, NK cells (Palucka et al., 2003; Ishikawa et al., 2005; Gimeno et al., 
2004). 
Recent reports demonstrate the availability of human hematopoietic 
progenitor cells positive for the expression of the antigen CD133. The majority 
of CD133+ progenitor cells coexpress the antigen CD34 (Bhatia, 2001, Gordon 
et al., 2003; Götze et al., 2007). Pioneering studies of transplantation with 
sorted human CD133+/CD34+ cells in NOD-scid mice showed a higher 
engraftment compared to CD133-/CD34+ cells (Handgretinger et al., 2003). In 
recent studies, CD133-sorted human progenitor cells, expanded ex-vivo through 
a 3 week culture with a mix of cytokines and growth factors, were analyzed for 
the presence of long term severe combined immunodeficient  
SCID-repopulating cells (SRCs). CD133+ cells showed a superior frequency of 
SRCs and a significantly superior ability to generate progenitor cells in vitro 
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than CD34+ hematopoietic cells (Suzuki et al., 2006). In vivo, when 
transplanted in NOD-scid or NOD-scid β2mnull or γcnull mice, CD133+ 
progenitor cells showed a high percentage of reconstitution of human immune 
populations also at low cell doses (Suzuki et al., 2006, Boxall et al., 2009).  
 
Engraftment strategies  
Different transplantation strategies to establish humanized mice models 
have been described in which immunodepressed scid or NOD-scid mice were 
engrafted with human hematopoietic tissues and cells to obtain the 
reconstitution of a functional human immune system. Humanized mice were 
obtained by implanting directly mature human immune cells. The first report 
dated back to early 1980s, (Bosma et al., 1983; Mosier et al., 1988) when it was 
found that the intraperitoneal transplantation of human peripheral blood 
mononuclear cells (PBMC) into scid mice resulted in the establishment of a 
partially functional human immune system. High rate of reconstitution were 
obtained after transfer of human PBMC in severely combined immunodeficient 
mice as NOD-scid and NOD-scid β2Mnull (Berney et al., 2001). PBMC models 
are mainly used in short-term analysis (no more than 4 weeks long) of human 
immune functions such as immunological disorders, analysis of antigen recall 
responses and investigation of allograft rejection. Most of the investigation in 
this experimental model could be limited in time due to the onset of xenogeneic 
graft-versus-host disease symptoms that can be monitored by weight loss in 
recipient mice (Pearson et al., 2008). Furthermore, the early investigated 
humanized models showed substantial limitations not only in the duration of 
reconstitution but also in the functionality of the engrafted human immune 
system (Manz, 2007, Legrand et al., 2006) mainly due to the leakiness of the 
immunodepressed murine phenotype. The intact macrophage and NK function 
of such murine models could control the migratory ability of PBMC through 
the peritoneal cavity causing low levels of human PBL engraftment.  
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Another approach to establish humanized mice was through engraftment of 
human fetal tissues such as thymus and liver in immunocompromised mice. 
The main advantage of this reconstitution model is that human lymphocytes 
develop from engrafted human progenitor cells, undergo negative selection 
during differentiation of human T and B lymphocytes and are tolerant to murine 
host antigens. Furthermore, the transplantation of fetal human thymus and liver 
tissue beneath the kidney capsule of immunocompromised mice resulted in the 
development of a well vascularized human thymus-like organ that can 
temporarily sustain human hematopoiesis. Human immune cells colonized both 
central lymphoid tissues (thymus and bone marrow) and secondary lymphoid 
organs (spleen and lymph nodes) (Lan et al., 2006; Joo et al., 2009; Lepus et 
al., 2009). A further increase in human colonization was achieved with the 
concomitant transplantation of liver-derived HSCs resulting in the development 
of a functional human immune system as demonstrated by skin xenograft 
rejection (Lan et al., 2006). The multi-lineage reconstitution of functional 
human immune T, B and NK cells in immunodeficient mice was also achieved 
through the injection of HSCs from different sources such as bone marrow, 
mobilized PBMC or umbilical cord blood (Legrand et al., 2006).  
In pioneering works, the efficiency of engraftment by intraperitoneally 
engrafted HSCs resulted extremely age-dependent, likely due to the lower 
number and activity of phagocytic cells in newborn compared to adult mice 
(Gimeno et al., 2004). Pre-conditioning regimens were adopted to gain a long 
lasting and functional engraftment.  
The most important achievement in engraftment ability was obtained 
through the injection of HSCs in irradiated mice. Sublethal irradiation 
schedules may differ due to the radiosensitivity of each murine model and 
mouse age (Pearson et al., 2008). Sublethal irradiation like treatments with 
chemical reagents, such as busulfan treatment of pregnant dams, could improve 
human cell engraftment resulting in depletion of mouse HSCs, increased 
concentrations of growth factors and chemoattractants and “space” for the 
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development and repopulation of human HSCs and immune cells in recipient 
mice (Robert-Richard et al., 2006; Gorantla et al., 2007). Furthermore, since 
liver is the main organ to contribute to perinatal hematopoiesis, and the hemato-
lymphoid system undergoes a great expansion during the first weeks of life, 
Traggiai et al. set up a protocol of HSC engraftment which consisted in the 
transplantation of human hematopoietic CD34+ stem cells in the liver of 
newborn Rag2-/-;γc-/- mice which had received a sublethal dose of radiation. 
These mice showed human CD45+ lymphocytes in main lymphopoietic organs 
such as thymus, bone marrow, spleen and lymph nodes and the development of 
human T, B, NK and dendritic cells (Traggiai 2004).  
Other treatments aimed at reducing the innate immune cells in recipient 
mice before the injection of HSCs. In NOD-scid mice, treatment to reduce NK 
cell population were performed by administering anti-asialo GM1, anti-CD122 
or anti-IL-2R βchain (TMβ-1) antibodies (Yoshino et al., 2000; Legrand et al., 
2006). Macrophage depletion was achieved treating recipient mice with 
liposome-encapsulated dichloromethylene-biphosphonate (Rozemuller et al., 
2004).  
Different papers have been recently published in which comparisons in the 
engraftment ability of different immunodeficient murine models (Lepus et al., 
2009) or of different sources of HSC (Matsumura et al., 2003; Lepus et al., 
2009) were made. The variability of the reconstitution seemed to be mainly 
linked to the degree of immunodepression of the host murine model. NOG mice 
and Rag2-/-;γc-/- mice were the more permissive hosts for the engraftment of 
human stem cells and the reconstitution of a human immune system because of 
their severe combined immunodepression. Studies comparing the engraftment 
ability of HSC from different sources in immunodeficient hosts did not showed 
differences in the maturation or functional ability of the engrafted human 
immune cells. The high variability of reconstitution observed in mice engrafted 
with different HSCs could be mainly linked to the number of injected cells or to 
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differences in the purification procedure or storage and not to the cell source 
(Chicha et al., 2005; Legrand et al., 2006).  
 
AIM 
The specific aim of this task was to establish a murine model of human 
immune response to evaluate the efficacy of immunological antitumor 
approaches. The aim of this work had two tasks: 1) to set up a model for a 
functional human immune system in Rag2-/-;γc-/- mice comparing the efficiency 
of reconstitution by different hematopoietic progenitor cells, and 2) to 
immunize humanized mice with tumor cell vaccines expressing human HER-2 
and to analyze anti-human HER-2 responses.  
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RESULTS 
Reconstitution of human immune system in Rag2-/-;γc-/- mice 
Newborn (0-2 days old) Rag2-/-;γc-/- mice were subletally irradiated and 
injected intrahepatically with 1-2 x 105 CD34+ or CD133+ cord blood 
progenitor cells. At 5-9 weeks of age, the peripheral blood leukocytes of Rag2-/-
;γc-/- mice were analyzed to assess the entity of the in vivo human repopulation. 
The reconstitution was evaluated as the percentage of circulating human CD45+ 
cells on the whole circulating leukocytes. Similar levels of engraftment were 
observed in mice reconstituted with CD34+ or CD133+ progenitors, with 
median levels of human CD45+ cells of 41% and 44%, respectively. A wide 
majority of mice (more than 80%) showed a percentage of circulating human 
CD45+ cells ≥10% of all circulating leukocytes (Figure 7A). Most human 
leukocytes exhibited a CD19+ phenotype (B cells), while CD3+ cells 
(corresponding to T cells) were rarely observed (Figure 7B and 7C). 
To determine whether B cells in recipient mice were functional, plasma 
samples were analyzed for the presence of human immunoglobulins.  
Rag2-/-;γc-/- mice transplanted with both CD34+ or CD133+ cord blood cells 
showed detectable levels of human IgM with a median serum concentration of 
about 3.0 μg/mL (Figure 7D). A significantly different concentration of human 
IgG was observed (p<0.05, non parametric Mann Whitney test). At 5-9 weeks 
of age, a fraction of mice reconstituted with CD34+ progenitor cells already 
showed IgG, while mice reconstituted with CD133+ progenitors showed almost 
undetectable human IgG levels (Figure 7E).  
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Figure 7. Reconstitution of Rag2-/-;γc-/- mice with human CD34+ (circles) or 
CD133+ (triangles) cord blood cells: hematopoietic cell engraftment and 
differentiation in the peripheral blood at 5-9 weeks of age. A: overall reconstitution 
rate expressed as percentage of human CD45+ leukocytes over total number of leukocytes. B: 
percentage of human CD3+ cells over total human CD45+ leukocytes. C: percentage of human 
CD19+ lymphocytes over total human CD45+ leukocytes. D: serum IgM levels. E: serum IgG 
levels. * = p<0.05 (non parametric Mann Whitney test).  
PBC: peripheral blood cells. Horizontal bars indicate median values of each series. 
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Kinetics of human reconstitution 
The kinetics of human leukocyte populations was analyzed in a subgroup 
of humanized mice. The human immune reconstitution was almost stable up to 
about 14-16 weeks of age (Figure 8A), then a slow decrease in the percentage 
of circulating human CD45+ leukocytes for mice engrafted with both types of 
human progenitor cells was observed up to 35-39 weeks of age (data not 
shown).  
Mice engrafted with CD34+ progenitors showed a significantly faster 
increase of the human CD3+ cell population compared to mice engrafted with 
CD133+ progenitors (p<0.05, Mann Whitney test at 14-16 weeks of age) (figure 
8B). Rise of human CD3+ population was paralleled by a decrease of human 
CD19+, which almost disappeared from the peripheral blood at about 20-25 
weeks of age (data not shown). In mice reconstituted with CD133+ progenitors, 
CD19+ lymphocytes remained high within the 14-16 weeks and significantly 
different from the values detected in mice reconstituted with CD34+ progenitors 
(p<0.05, Mann Whitney test) (Figure 8C). On the whole, CD19+ population 
appeared rapidly, then decreased concomitantly to CD3+ rise, in agreement with 
data reported by Traggiai (Traggiai et al., 2004). However a slower switch 
between CD19+ and CD3+ was observed in mice reconstituted with CD133+ 
progenitors than with CD34+ progenitor cells. 
Mice reconstituted with CD34+ and CD133+ progenitors showed a similar 
increase in human IgM serum levels up to 14-16 weeks after transplantation 
when circulating IgM reached median values of 13.5 μg/mL and 23 μg/mL, 
respectively (Figure 8D). Concerning IgG (Figure 8E), the difference in IgG 
production observed at the initial testing (see also Figure 7E) then decreased 
and at 14-16 weeks after reconstitution serum levels reached median values of 
4.1 μg/mL versus 9.1 μg/mL, for mice engrafted with CD34+ cells or CD133+ 
cells, respectively. 
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Figure 8. Kinetics of human leukocytes and immunoglobulin levels in peripheral 
blood of mice humanized with CD34+ (circles) or CD133+ (triangles) cord blood 
cells. A: percentage of human CD45+ leukocytes over total number of leukocytes. B: 
percentage of human CD3+ lymphocytes over total human CD45+ leukocytes. C: percentage of 
human CD19+ lymphocytes over total human CD45+ leukocytes. D: serum IgM levels. E: 
serum IgG levels. * = p<0.05 (non parametric Mann Whitney test). PBC: peripheral blood cells. 
Horizontal bars indicate median values of each series. 
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Cell vaccination of humanized Rag2-/-;γc-/- mice  
To verify the functionality of the  human immune system originated by 
CD34+ and CD133+ engrafted progenitors, and the ability to induce a specific 
immune response after vaccine stimulation, humanized Rag2-/-;γc-/- mice with 
≥10% of human leukocytes at the first test (5-6 weeks) were enrolled in 
protocols of cell vaccination with a cell vaccine highly positive for the 
expression of human HER-2 oncogene. In each reconstitution experiment, mice 
were randomized in two groups: vaccinated and treated mice. 
The vaccination protocol consisted of two cycles of treatment based on a 
four-week schedule. Each cycle comprised 4 administrations scheduled in 2 
weeks followed by a week of five daily administrations of human recombinant 
Interleukin (IL)-12 as vaccine adjuvant, and by a week of rest. Cell lines used 
as vaccines were a human ovary carcinoma cell line (SK-OV-3) and a murine 
mammary carcinoma cell line transduced with the huHER-2 gene (1E-huHER-
2). After each cycle of vaccination, mice were bled to determine the level and 
phenotype of human lymphocytes and human immunoglobulin production to 
study changes in the immune parameters linked to vaccination. Since the two 
cell vaccines used gave similar results for each of the studied parameters, data 
will be presented cumulated hereafter.  
In mice reconstituted with CD34+ progenitors (Figure 9) vaccination did 
not significantly modify the kinetics of human circulating CD45+ cells as well 
as that of CD3+ and CD19+ populations. Both total IgM and IgG levels were not 
different in control and vaccinated CD34+ reconstituted mice. 
Mice engrafted with CD133+ progenitor cells also showed a similar 
kinetics of human CD45+ leukocytes in control and vaccinated groups (Figure 
10A). Interestingly, vaccinated mice showed a high heterogeneity in the 
percentage of human CD3+ lymphocytes compared to control mice resulting in 
a slightly increased median level since 10-11 weeks after reconstitution 
(corresponding at the end of the first treatment cycle) (p=0.06) (Figure 10B). 
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On the other side, the median concentration of human CD19+ lymphocytes in 
the peripheral blood of vaccinated mice was lower compared to control mice 
since 10-11 weeks after reconstitution (p=0.06) (Figure 10C). Vaccination did 
not modify total IgM or IgG levels (Figure 10D and 10E). 
Comparison between vaccinated mice reconstituted with CD34+ or 
CD133+ progenitors showed a different kinetics of human circulating 
leukocytes. CD45+ cells in CD133+-reconstituted vaccinated mice remained 
significantly higher than in CD34+-reconstituted vaccinated mice at the 
detection time of 10-11 and 14-16 weeks (p<0.05, non parametric Mann 
Whitney test). Nevertheless, the kinetics of human CD3+ and CD19+ 
lymphocyte populations were similar in vaccinated mice of the two 
reconstitution groups. Concerning immunoglobulin levels, CD133+-
reconstituted vaccinate mice showed significantly higher levels of circulating 
IgM than CD34+-engrafted vaccinated mice 10-11 and 14-16 weeks after 
transplantation (p<0.05, non parametric Mann Whitney test). All vaccinated 
mice reached similar levels of circulating IgG at each detection time.  
The induction of a specific anti-vaccine humoral response was analyzed 
with cytofluorometric assays to detect the presence of human immunoglobulins 
(both IgM and IgG) able to bind the human cells SK-OV-3 positive for human 
HER-2. More specific assays to detect human anti-HER-2 immunoglobulins 
were performed through ELISA or Western blot experiments. All these 
methods did not evidence specific anti-vaccine humoral responses in CD34+- as 
well as in CD133+-reconstituted mice (data not shown). 
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Figure 9. Kinetics of human leukocytes and immunoglobulin levels in peripheral 
blood of control (open circles) or vaccinated (red circles) mice reconstituted with 
CD34+ progenitor cells. Mice were analyzed before (pre 5-6 weeks of age) and after every 
vaccination cycle (10-11 and 15-16 weeks after reconstitution) to detect human leukocytes and 
immunoglobulins in the peripheral blood. A: percentage of human CD45+ leukocytes over total 
number of leukocytes. B: percentage of human CD3+ lymphocytes over total human 
CD45+leukocytes. C: percentage of human CD19+ lymphocytes over total human CD45+ 
leukocytes. D: serum IgM levels. E: serum IgG levels. PBC: peripheral blood cells. Horizontal 
bars indicate median values of each series. 
 61
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pre (5-6) 10-11 14-16
0
20
40
60
80
100
hCD45+
%
 o
ve
r P
B
C
pre (5-6) 10-11 14-16
0
20
40
60
80
100
hCD19/CD45+
%
 o
ve
r 
to
ta
l h
C
D
45
+
pre (5-6) 10-11 14-16
0
20
40
60
80
100
hCD3/CD45+
%
 o
ve
r 
to
ta
l h
C
D
45
+
pre (5-6) 10-11 14-16
0.1
1
10
100
1000
serum IgG
< 0.01
(μg
/m
L)
pre (5-6) 10-11 14-16
0.1
1
10
100
1000
serum IgM
< 0.02
(μg
/m
L)
A
B C
D E
weeks after reconstitution with human CD133+ progenitors
 
Figure 10. Kinetics of human leukocytes and immunoglobulin levels in 
peripheral blood of control (open triangles) or vaccinated (red triangles) mice 
reconstituted with CD133+ progenitor cells. Mice were analyzed before (pre 5-6 weeks 
of age) and after every vaccination cycle (10-11 and 15-16 weeks after reconstitution) to detect 
human leukocytes and immunoglobulins in the peripheral blood. A: percentage of human 
CD45+ leukocytes over total number of leukocytes. B: percentage of human CD3+ lymphocytes 
over total human CD45+leukocytes. C: percentage of human CD19+ lymphocytes over total 
human CD45+leukocytes. D: serum IgM levels. E: serum IgG levels. PBC: peripheral blood 
cells. Horizontal bars indicate median values of each series. 
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Localization and persistence of human leukocytes in lymphoid 
organs of vaccinated mice 
To further compare the two progenitors used for reconstitution (CD34+ and 
CD133+), cells from several lymphoid organs (spleen, thymus, bone marrow 
and mesenteric lymph node) of vaccinated mice were analyzed for the presence 
of human cells at two different time intervals: at the end of vaccination protocol 
(16 weeks) and after about two further months (23 to 26 weeks of age). Human 
leukocytes were found in all investigated lymphoid organs up to 23-26 weeks 
of age (Figure 11). Similar proportions of human engraftment for mice 
reconstituted with the two progenitors were observed at 16 weeks of age with 
thymus and mesenteric lymph node almost completely reconstituted by human 
cells. In fact in non-reconstituted Rag2-/-;γc-/- mice thymus and mesenteric 
lymph node are commonly not observed due to an almost complete lack of 
lymphoid cells (data not shown). The percentage of human CD45+ leukocytes 
in lymphoid organs of CD34+ reconstituted mice was almost stable up to 23-26 
weeks, whereas for CD133+ reconstituted mice a significant decrease in thymus 
was observed at 23-26 weeks (Figure 11).  
Concerning CD3+ and CD19+ differentiated populations, thymus from both 
groups of reconstituted mice only showed CD3+ cells, increasing along time. At 
16 weeks of age, thymic leukocytes in mice reconstituted with both progenitors, 
showed a little proportion of CD45+ cells showing a bright expression of human 
CD3, while all the other cells showed an intermediate, low or negative 
expression of human CD3. Furthermore, at this time, the thymus of 
reconstituted mice was rich in immature leukocytes double positive for the 
expression of human CD4 and CD8 (median levels of 79% and 72% of total 
leukocytes in mice reconstituted with CD34+ and CD133+ progenitors, 
respectively) that decreased along time (median levels of 67% and 24% of total 
leukocytes in mice reconstituted with CD34+ and CD133+ progenitors, 
respectively at 23-26 weeks of age). Spleen, bone marrow and mesenteric 
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lymph node contained both CD3+ and CD19+ populations, showing kinetics 
similar to those observed in the peripheral blood of untreated reconstituted mice 
mentioned above, with CD3+ increasing and CD19+ decreasing fractions along 
time. A more marked decrease of CD19+ population was found in bone marrow 
of CD133+ reconstituted mice at 23-26 weeks in comparison to CD34+ 
reconstituted mice, that reached statistical significance when comparing the 
absolute number of CD19+ cells (data not shown). Furthermore, percentage of 
human CD3+ cells in spleen, thymus and bone marrow of CD133+-reconstituted 
mice was significantly increased at 23-26 weeks of age compared to 16 weeks 
of age, while percentage of human CD19+ cells in spleen and bone marrow of 
CD133+ reconstituted mice significantly decreased along time (Figure 11). 
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Figure 11. Human leukocytes repopulation of lymphoid organs in vaccinated mice 
reconstituted with CD34+ (grey bars) or CD133+ (black bars) progenitor cells. 
Mice reconstituted with CD34+ or CD133+ cord blood cells were sacrificed after the end of the 
vaccination protocol (16 weeks) or after 2 further months of observation (23-26 weeks). Mean 
± SEM from 3 to 4 animals is shown for each group. * = p<0.05 versus mice engrafted with 
CD34+ progenitors at the same age; # = p<0.05 versus 16 weeks of age (non parametric Mann 
Whitney test). 
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Tumor growth in vaccinated mice 
To verify if cell vaccination was able to activate the engrafted human 
immune system to prevent or delay the growth of a human HER-2 positive 
tumor cell line (SK-OV-3), mice reconstituted in a same experimental session 
to reduce variability due to human cord blood cell samples and injection, were 
randomized into control or vaccinated group and, after the second vaccination 
cycle, challenged with s.c. injected SK-OV-3. Age- and sex-matched naïve (not 
irradiated nor engrafted with human progenitor cells) mice were challenged in 
parallel. As illustrated in Figure 12, reconstituted vaccinated mice showed 
tumor growth kinetics superimposable to that of reconstituted control mice. 
Humanized mice showed a reduced tumor growth rate compared to naïve mice. 
In this preliminary experiment, we observed that irradiated and reconstituted 
mice had a lower weight than naïve mice. To explain if tumor growth rate could 
be affected by metabolism changes due to irradiation, new experiments are 
ongoing to better correlate mice weight and tumor growth in naïve irradiated 
and reconstituted mice. On the whole, growth of SK-OV-3 cells was not 
modified by vaccination. 
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Figure 12. SK-OV-3 tumor growth in control or vaccinated Rag2-/-;γc-/- mice 
reconstituted with CD34+ or CD133+ progenitor cells (left) and naïve Rag2-/-;γc-/- 
mice (right). Mice received the subcutaneous injection of 105 SK-OV-3 cells.  
Black symbols indicate control humanized mice (left panel) and naïve mice (right panel). Red 
symbols indicate mice vaccinated with HER-2 positive cell vaccines. Circles indicate mice 
engrafted with CD34+ progenitor cells, triangles indicate mice engrafted with CD133+ 
progenitor cells. 
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In vitro proliferation and IFN-γ production 
To study if cell vaccination was able to induce T cell activation, control 
and vaccinated humanized mice were sacrificed at the end of the vaccination 
and human IFN-γ production by spleen cells was evaluated. Human leukocytes 
(enriched from spleen cell suspensions through positive magnetic sorting for 
human CD45 antigen) were cultured alone or in the presence of proliferation-
blocked SK-OV-3 vaccine cells for six days. Then culture supernatants were 
collected and analyzed for the presence of human IFN-γ. IFN-γ is a cytokine 
released by antigen-activated T-cells and NK cells after IL-12 stimulation.  
Human CD45+ splenocytes from control CD34+-reconstituted mice 
produced undetectable or very low levels of human IFN-γ after spontaneous 
culture, partially increased after in vitro restimulation with SK-OV-3 cells 
(Figure 13). Human CD45+ spleen cells of vaccinated CD34+-reconstituted 
mice were able to produce human IFN-γ both when cultured alone and with 
vaccine cells (Figure 13). Both control and vaccinated CD133+ reconstituted 
mice showed no production of human IFN-γ by spleen cells cultured alone. 
Restimulation with vaccine cells did not led to significant IFN-γ production 
(Figure 13). In conclusion, the higher IFN-γ production found in culture of 
vaccinated CD34+–reconstituted spleen cells with comparison to control 
CD34+-reconstituted spleen cells suggests that some level of immune 
stimulation was actually obtained in these mice. 
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Figure 13. Human IFN-γ release by human CD45+ spleen cells of mice 
reconstituted with CD34+ (circles) or CD133+ (triangles) progenitors and enrolled 
in cell vaccination protocols. Spleen cells were collected from age-matched control (open 
symbols) or vaccinated (red symbols) mice after two vaccination cycles and incubated in vitro 
for 6 days alone or with mitomycin C-treated cells expressing human HER-2 (SK-OV-3 cells). 
Supernatants were collected to measure the release of human IFN-γ through cytokine ELISA 
assays. Horizontal bars indicate median values of each series. 
 
 
 
The results reported above will be included in a manuscript in 
preparation. 
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DISCUSSION 
Humanized mice are a promising translational tool for the in vivo study of 
human hematopoiesis and immunity. The development of human adaptive 
immune system in immunodepressed mice reconstituted with human 
progenitors took advantage from the development of new more permissive 
immunodepressed murine models and from the definition of more efficient 
engraftment procedures. In 2004, Traggiai and colleagues described the 
development of HIS (human immune system) mice after newborn intrahepatic 
injection of CD34+ cord blood progenitors. Because the hematolymphoid 
system massively expands during the first weeks of life, transplantation of stem 
and progenitor cells in the liver of newborn mice was able to provide a 
permissive environment for cell engraftment and expansion. Starting from this 
engraftment procedure, the work here reported was developed with two main 
goals: 1) to study the repopulating potential of CD133+ progenitors isolated 
from cord blood, and 2) to evaluate the possibility to exploit CD34+ or CD133+ 
reconstituted mice to study human immune responses against HER-2 
expressing tumor cells. 
Irradiated Rag2-/-;γc-/- newborn mice received the injection of one of two 
different subsets of hematopoietic progenitor cells (CD34+ or CD133+ cord 
blood cells). On the whole, about 80% of mice showed a percentage of 
circulating human CD45+ leukocytes ≥10% of all leukocytes in short term 
assays (5-9 weeks), with a wide heterogeneity in CD45+ levels among 
individual mice.  
CD133+ progenitors gave slightly higher levels of circulating human 
CD45+ leukocytes from 10 to 16 weeks after transplantation maybe correlating 
with the content of SCID repopulating cells (SRCs) in CD133+ progenitor cells 
(Suzuki et al., 2006). The reconstitution was stable up to 15-20 weeks of age, as 
data from blood samples revealed, then human leukocytes slowly decreased. 
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Progenitor cells showed differentiation ability in the two human major 
lymphoid subsets (CD3+ T cells and CD19+ B cells) in transplanted mice, with 
an early onset of circulating CD19+ cells which then decrease while CD3+ 
increase. However, some differences were detectable in mice engrafted with 
different progenitor cells. CD133+-reconstituted mice showed a significantly 
higher percentage of human CD19+ lymphocytes than CD34+-reconstituted 
mice since the 10th week of age. Conversely, in these mice, at 14 to 16 weeks of 
age, human CD3+ lymphocyte percentage in the peripheral blood is 
significantly lower than in mice transplanted with CD34+ cells. 
To verify human lymphocyte activity, immunoglobulin levels were 
detected in serum samples of humanized mice. At the first detection time, about 
the 42% of mice transplanted with CD34+ progenitor cells already showed 
detectable levels of serum IgG, whereas IgG were undetectable in almost all 
mice reconstituted with CD133+ cells. On the other side, the two repopulating 
approaches showed comparable IgM levels. These data suggested that CD133+ 
cells showed a more staminal behavior perhaps due to the major content in 
SRCs than CD34+ sorted cells. Nevertheless, immunoglobulin concentration 
increased over time in the peripheral blood in all humanized mice reaching 
similar median levels, even though, such levels were two logs or one log lower 
than that measured in human adults and wild type laboratory mice, respectively 
(Traggiai et al., 2004; Baenziger et al., 2006).  
Few studies described the induction of both humoral and cellular adaptive 
immune responses in Rag2-/-;γc-/- humanized mice, essentially against viral 
pathogens (Traggiai et al., 2004; Baenziger et al., 2006; Gorantla et al., 2007, 
Kwant-Mitchell et al., 2009a). A future human application of anticancer cell 
vaccine-based strategies will require specific studies aimed at the definition, in 
preclinical models, of the optimal conditions for a successful translation. To 
study if humanized mice could be a suitable model to study human immune 
anti-tumor response, a standardized anti-HER-2 vaccination protocol was tested 
(Nanni et al., 2001; De Giovanni et al., 2004). Mice engrafted with CD34+ and 
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CD133+ cells were enrolled in protocols of cell vaccination in 4 weeks based 
cycles as described. No differences were detected in the kinetics of human 
leukocytes in the peripheral blood of vaccinated or control mice humanized 
with the different progenitor populations even though CD133+ reconstituted 
vaccinated mice showed significantly higher levels of circulating CD45+ 
leukocytes at 10-11 and 14-16 weeks after reconstitution compared to CD34+ 
reconstituted vaccinated mice. Interestingly, in vaccinated mice engrafted with 
CD133+ progenitors, the percentage of circulating human CD19+ and CD3+ 
cells became extremely heterogeneous compared to control mice. Namely, 14-
16 weeks after reconstitution, human CD19+ cells in vaccinated mice showed a 
reduced median percentage compared to control mice and human CD3+ 
lymphocytes showed an increased median percentage. 
As reported human B cells are functional and able to produce and release 
human immunoglobulins in the peripheral blood. Vaccinated mice reconstituted 
with each of the two progenitor cells did not show significant changes in the 
total concentration of human IgM or IgG compared to control mice, even 
though vaccinated mice reconstituted with CD133+ progenitors showed 
significantly higher levels of human circulating IgM than vaccinated mice 
reconstituted with CD34+ progenitors. Specific anti-vaccine antibodies were 
detected in none of the vaccinated mice. 
All engrafted mice showed human CD45+ cells in different lymphoid 
organs as bone marrow, spleen, thymus and mesenteric lymph node. Spleen and 
thymus of reconstituted animals enlarged, as reported in different papers 
(Traggiai et al., 2004; Chicha et al., 2005; Kwant-Mitchell et al., 2009b) and 
displayed quite the same size of age-matched wild-type mice. Furthermore, 
reconstituted mice had detectable mesenteric lymph nodes, whereas lymph 
nodes were never detected in naïve mice. Interestingly, comparing vaccinated 
mice, CD133+-reconstituted mice showed a significantly reduced level of 
thymus engraftment from the 20th to 29th week of age while other lymphoid 
organs showed a similar or slightly superior human leukocyte persistence than 
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CD34+-reconstituted mice. CD3+ and CD19+ human population efficiently 
differentiate in the lymphoid organs of vaccinated mice reconstituted with 
either progenitor cell.   
The long-term loss in human CD45+ cells, and mainly the absence of 
specific responses, were probably consequences of the absence of growth factor 
and cytokines that could sustain human immune leukocytes. Some murine 
hemato-lymphoid development relevant cytokines are not active on human 
immune cells (i.e. IL-2, IL-3, IL-6 and macrophage colony-stimulating factor) 
(Manz, 2007). The lack of cross-reactivity in cytokine function suggests that 
the administration and/or engineered expression of human factors able to keep 
human leukocyte homeostasis and induce their differentiation (Sun et al., 2006; 
Huntington et al., 2008; Schmidt et al., 2008; Chen et al., 2009) or the 
expression of human histocompatibility molecules to support human 
lymphocytes selection (Camacho et al., 2007) could improve human immune 
system maintenance.  
The main actors of the immune response elicited by a similar formulation 
of cell vaccine were anti-p185neu antibodies and interferon gamma (IFN-γ) 
(Nanni et al., 2001; De Giovanni et al., 2004). In vaccinated humanized mice 
we were not able to detect the presence of human immunoglobulin specific for 
the oncoantigen HER-2/neu. 
Vaccinated and control mice received the subcutaneous injection of human 
HER-2 positive tumor cells to test whether cell vaccination could activate 
human immune system to block or delay tumor growth. Humanized mice 
showed a reduced tumor growth rate compared to naïve mice, but no difference 
between control and vaccinated mice was found. Further investigations are 
ongoing to verify if the observed reduced tumor growth in humanized mice was 
due to irradiation or the consequence of some activity by human repopulating 
cells. Newly published data suggested that natural killer activity of engrafted 
human immune system could control tumor growth rate in  
Rag2-/-;γc-/- humanized mice challenged with K562 cells (Kwant-Mitchell et al., 
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2009b). Further investigations to verify the contribution of the innate immunity 
in our model will be performed. 
Some evidence of activity by human immune cells was actually found in 
experiments of in vitro culture of human splenocytes vaccinated  
CD34+-reconstituted mice: human IFN-γ production by cells from vaccinated 
mice (and not from controls) suggests that a T helper 1 immune stimulation was 
elicited by the vaccine. 
All these data supported the hypothesis that the transplantation of human 
stem cells could allow a partially functional human immune system in which to 
study approaches of cancer vaccination and mimic the physiology of a human 
immune response. However limitations still remain like the low and quite 
undetectable human adaptive immune response. The generation of furtherly 
improved humanized models with both a decreased host innate immunity and 
the support of human transgenic hystocompatibility molecules and cytokines to 
reproduce a suitable environment for human cells maintenance and activation 
should therefore be pursued (Shultz et al., 2007; Zhang et al., 2008).  
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CONCLUSIONS 
 
This thesis deals with the evaluation in a new preclinical murine model of 
two important issues for successful preclinical studies of anticancer approaches. 
On one side, the characterization of a suitable murine model in which to 
reproduce and study the physiology and the pathobiology of human cancer 
growth and metastasis, on the other side, the set up of a humanized model for 
modeling human immune antitumor responses.  
The experimental studies of human tumor growth and metastasization as 
well as of targeted therapies required suitable immunodeficient murine models. 
Comparative studies reported different growth patterns in different murine 
models (Garofalo et al., 1993); differences were mostly attributable to the 
residual adaptive immune activity (i.e., granulocytes and natural killer cells) 
(Lozupone et al., 2000; Dewan et al., 2005). Rag2-/-;γc-/- mice completely lack 
B, T and NK cell activity. Studies reported here showed that such severe 
combined immunodepression allow a better expression of the metastatic 
potential of human sarcomas than in nude mice both from a quantitatively and 
quantitatively point of view. Moreover, human sarcomas were able to give 
metastases in the liver of Rag2-/-;γc-/- mice, while this organ was not affected by 
metastases in nude mice. This phenomenon could be explained as a 
consequence of the profound immunodepression of the experimental model 
(including a total absence of NK cells). Liver metastatic localization could be 
driven by hepatic factors acting as growth or chemoattractive factors, such as 
liver-produced IGFs. The potential usefulness of this potent model was 
suggested by the antimetastatic activity of targeted and gene-based therapeutic 
approaches successfully analyzed. 
The development of humanized mice by engraftment with human 
hematopoietic stem cells could be a potential tool to study human immune 
system development and function. In this thesis, two different cord blood 
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progenitor cells were compared in terms of ability to engraft and give rise to a 
functional human immune system. Immune-based antitumor strategies could 
take advantage from the study in suitable preclinical models that allow the 
simulation and understanding of human immune responses. Here we showed 
the changes in the repopulation and differentiation of the human immune 
system of transplanted mice treated with tumor cell vaccines expressing human 
HER-2. Further analysis to detect human immune system functionality are 
under investigation.  
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MATERIALS AND METHODS 
 
MICE  
Rag2-/-;γc-/- breeders were kindly provided by Drs T. Nomura and M. Ito of 
the Central Institute for Experimental Animals (CIEA) (Kawasaki, Japan). 
Mice were bred under sterile conditions in our facilities. Athymic Crl:CD-1-
Foxn1nu/nu mice (here referred to as nude mice) were purchased from Charles 
River Italy and kept under sterile conditions. Experiments were authorized by 
the institutional review board of the University of Bologna and done according 
to Italian and European guidelines. 
 
TUMOR GROWTH AND METASTATIC SPREAD OF 
HUMAN TUMOR CELL LINES IN RAG2-/-;γc-/- MICE  
Cell lines 
To study the metastatic behavior of human tumor cell lines, Rag2-/-;γc-/- 
mice received the intravenous injection of a cell suspension of sarcoma or 
carcinoma tumor cell lines. The panel of human sarcoma cell lines consisted in 
Saos-2 osteosarcoma, U2OS osteosarcoma, TC-71 and 6647 Ewing’s sarcoma 
cell lines, gift from T. Triche (Lollini et al., 1998), SJ-Rh4 alveolar 
rhabdomyosarcoma (Shapiro et al., 1993) and RD/18 and RD/12, two clonal 
derivatives of the RD embryonal rhabdomyosarcoma cell line (Lollini et al., 
1991). Human carcinoma cell lines were: HepG2 hepatocellular carcinoma 
(ATCC, USA), Caco-2 colo-rectal carcinoma (ATCC), HT-29 colon 
adenocarcinoma (ATCC), MCF7 mammary carcinoma and SK-OV-3 ovarian 
carcinoma, kindly provided by Dr. S. Ménard and S. Pupa, National Cancer 
Institute, Milan, Italy (Ricci et al., 2002). Osteosarcoma and Ewing’s sarcoma 
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cell lines were routinely cultured in Iscove’s modified Dulbecco’s medium 
(IMDM), rhabdomyosarcoma and colon carcinoma cell lines in Dulbecco’s 
modified Eagle’s medium (DMEM), mammary and ovarian carcinoma cell 
lines in RPMI-1640 medium. All media were supplemented with 10% fetal 
bovine serum (FBS). All cells were maintained at 37°C in a humidified 5% 
CO2 atmosphere with the exception of rhabdomyosarcoma cell lines, cultured 
in a humidified 7% CO2 atmosphere. All medium constituents were purchased 
from Invitrogen (Milan, Italy). 
 
Cell transfection 
To better localize and quantify tumor metastases, TC-71 cells were 
transfected with pEGFP-N1 plasmid (Clontech, Mountain View, CA) carrying 
the Enhanced Green Fluorescent Protein (EGFP) gene and a neomycin 
resistance gene expression cassette. TC-71 cells were seeded at the 
concentration of 3x105 cells/well in 6-well plates (Falcon, Oxnard, USA) in 
IMDM without serum and let to attach for 24 hours. Transfection was done 
with Fugene (Roche Diagnostics, Indianapolis, IN) at a 3:2 ratio (Fugene µl: 
DNA µg). 72 hours post transfection cells were harvested and seeded in 100 
mm dishes (Nunc) in medium supplemented with geneticine (G418) 
(Invitrogen) (500 μg/mL). Single transfectant colonies which stably expressed 
EGFP were isolated using sterile glass cloning cylinders. Derived cell lines 
were injected in Rag2-/-;γc-/- to induce experimental metastasis.  
To study the role of forced expression of myogenin in rhabdomyosarcoma 
cell lines differentiation, RD/12 cells were transfected with a myogenin 
expressing plasmid. Gene transduction was done with plasmid MD-R1-
Myogenin, derived from a previously described vector (Dotto et al., 1989) and 
kindly provided by Dr. Marco Crescenzi, Regina Elena Cancer Institute, Rome, 
Italy. MD-R1-Myogenin carries the 1.4 kb rat Myogenin cDNA under the 
control of the SV40 promoter and a neomycin resistance gene expression 
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cassette. Transfection was done by calcium phosphate precipitation (Invitrogen) 
with 2 μg of plasmid. Selection for stable transfectants was obtained through 
culture with DMEM + 20% fetal bovine serum containing 500 μg/mL of G418. 
Single transfectant colonies were isolated; control clones were isolated from 
cells transduced with the neomycin resistance gene alone. Myogenin expression 
was assessed by real-time reverse transcription-PCR.  
 
Metastasis induction 
Rag2-/-;γc-/- mice (9-20 weeks-old) and nude mice (5-6 weeks-old) received 
the intravenous (i.v.) injection of viable human tumor cells (see Tables for cell 
doses) in 0.4 ml phosphate-buffered saline (PBS) (Invitrogen). 24 hours prior to 
the i.v. injection of human tumor cells, nude mice were i.v. treated with  
anti-asialo GM1 antiserum (Wako, Dusseldorf, Germany), 0.4 ml of a 1:30 
dilution in PBS, to deplete NK activity (Kawano et al., 1986). Pilot experiments 
were performed to assess for each cell line at what time experimental 
metastases could be detected (see Tables). 
Mice were sacrificed and subjected to an accurate necropsy. Lungs were 
stained with black India ink to better outline metastases and fixed in Fekete’s 
solution. Lung and liver metastases were counted using a dissection 
microscope.  
During the necropsy, mice who received the i.v. injection of TC-71 EGFP 
clones were analyzed using a fluorescence imaging device PAN-A-SEE-Y, 
Panoramic Imaging System (Lightools Research, CA, USA). To detect TC-71 
EGFP metastases, filters were set up as follow: excitation filter at 470 nm 
wavelength, emission filter at 515 nm wavelength. Images were acquired 
through Qcapture software. 
Some experiments were performed in which human sarcoma cells were 
subcutaneously (s.c.) injected (see Table 2 for cell doses) to study tumor growth 
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ability and spontaneous metastasis induction. Multi-organ metastases were 
evaluated as reported above. 
 
Metastasis therapy 
NVP-BEZ235 (Novartis Institutes for BioMedical Research-Oncology, 
Basel Switzerland) is a dual small inhibitory molecule of PI3K/mTOR kinases 
involved in the signalling pathway downstream IGF1R (Serra et al., 2008). 
NVP-BEZ235 was formulated in 5-10 N-methyl-2-pyrrolidone 
(NMP)/polyethylene glycol 300 (PEG300) (Fluka) (10/90, v/v) (Serra et al., 
2008). Solutions (5 mg/mL) were prepared fresh each day of treatment as 
follows: the powder was dissolved in NMP, warmed in hot water (100°C) for 1-
2 minutes, the remaining volume of PEG 300 was then added. A dose of 50 
mg/kg was given per os daily starting from the day after cell injection. Mice 
received 3 drug administrations in the first week, and 5 drug administrations in 
the following weeks, for a total amount of 18 treatments. Mice were sacrificed 
5 days after the last treatment and subjected to an accurate necropsy as 
described above. 
 
Tumor cell growth and migration in conditioned media 
The human liver-derived cells, HepG2 and the murine hepatic cell line, 
MLP29.1C (mouse liver progenitor cell line) were used to investigate in vitro 
the molecular mechanisms involved in sarcoma cell line liver metastasization. 
MLP29.1C cells were routinely cultured in DMEM plus 10%FBS. 
To obtain conditioned medium, 4 x 105 human liver-derived HepG2 or 
MLP29.1c cells were seeded in RPMI + 10% FBS in 6-well plates. Cells were 
cultured for 48 h, then medium was removed, wells were washed three times 
with medium without serum and then serum-free DMEM or IMDM was added 
to each well. The incubation of the nearly confluent monolayer continued for 
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additional 24 hours, then conditioned medium was collected and cells 
conditioning the medium were harvested and counted. HepG2 conditioned 
medium was centrifuged at 2000 x g for 20 min at 4°C and stored at -20°C 
ready to be used. The same procedure was applied to aliquots of DMEM or 
IMDM serum-free medium to be used as control medium. For the growth assay 
in conditioned medium, human sarcoma and carcinoma cell lines were seeded 
in triplicate in 96-well plates, 104 cells/well, in 100 µl of HepG2 conditioned 
medium or control medium and cultured at 37°C in a 7% CO2 incubator. 
Proliferation was evaluated after 24 and 48 h of culture, by an assay employing 
sulfonated tetrazolium salt WST-1 (4-[3-(4-iodo-phenyl)-2-(4-nitrophenyl)-2H-
5-tetrazolio]-1,3-benzene disulfonate) (Roche Diagnostic, Mannheim, 
Germany). The measurement is based on the ability of viable cells to cleave 
tetrazolium salts by mitochondrial dehydrogenases. Briefly, 1/10 volume WST-
1 reagent was added in each well and after 2 h incubation, absorbance of the 
samples was measured using a microplate reader (Sunrise TECAN, 
Switzerland) at 450 nm with a reference wavelength of 620 nm with control 
medium alone as the background level.  
Migration assay was performed using Transwell chambers (Costar, 
Cambridge, MA) with 8 μm pore size, polyvinylpirrolidone-free polycarbonate 
filters. Conditioned or fresh medium was put in the lower compartments. 
Human tumor cultures were harvested and counted, 5 x 105 cells were washed 
and seeded in 100 μL of serum-free medium in the upper compartment of the 
Transwell chambers, and incubated for 18 h at 37°C in a 7% CO2 incubator. 
Cells migrated through the filter to reach the lower chamber were counted using 
an inverted microscope or harvested and counted in a Neubauer 
hemocytometer. Experiments of migration in conditions of IGF1R signalling 
neutralization were performed by incubation of the human tumor cells with 5 
μg/ml of the anti-human IGF1R monoclonal antibody clone αIR3 (Calbiochem, 
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Oncogene Research Products) in 100 μL of serum-free medium and then 
seeded in the upper compartment of the Transwell chamber. 
 
RECONSTITUTION OF RAG2-/-;γc-/- MICE WITH HUMAN 
HEMATOPOIETIC PRECURSORS 
Newborn mice were used for experiments of reconstitution of a human 
immune system as previously reported (Traggiai 2004). Briefly, newborn (0-2 
days old) Rag2-/-;γc-/- mice were subletally irradiated with 200 cGy twice (at a 
5-6 hour interval) from a Rontgen source at the Institute of Radiotherapy “L. 
Galvani”, Dipartimento di Fisica Sanitaria (Policlinico S. Orsola Malpighi, 
Bologna, Italy). Radiation treatments were performed by Dott. Fabrizio 
Romani. Within 24 hours, mice received the intrahepatic (i.h.) injection of 1-2 x 
105 CD34+ or CD133+ human cord blood progenitor cells (derived from single 
donors) purchased from ALLCELLS (Emerville, CA), or kindly provided by 
Professor Lemoli of the Department of Hematology and Oncologic Sciences 
“L. e A. Seragnoli”, University of Bologna.  
 
Cytofluorometric analysis of human cell engraftment 
To assess the level of engraftment, at 5-9 weeks of age and subsequently 
every 4 weeks, mice were bled from the ventral tail vein and reconstitution was 
examined as circulating human CD45+, CD3+ and CD19+ cells. Plasma samples 
from each mouse were collected to test human immunoglobulin levels. Cells 
harvested from the peripheral blood were treated with red blood cell lysis 
buffer. Then leukocytes were stained with PE-conjugated anti–human CD45 
(clone H130) and counterstained with FITC-conjugated anti-human CD3 (clone 
UCHT1) or FITC-conjugated anti-human CD19 (clone HIB19) for 30 minutes 
on ice. Other samples were stained with PE- and FITC-conjugated mouse IgG1, 
κ monoclonal immunoglobulin isotype control (clone MOPC-21). Multicolor 
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flow cytometric analysis of samples was performed with FACScan (Becton 
Dickinson, St Jose, CA). Mice with at least 10% of human CD45+ cells in the 
peripheral blood were subjected to long-term follow up or chosen for 
subsequent studies. To determine human cell engraftment in lymphoid organs, 
mice were sacrificed at different times after engraftment and lymphoid organs 
(spleen, bone marrow, thymus and mesenteric lymph node) were collected and 
single cell suspension were analyzed for the presence of human CD45+, CD3+ 
and CD19+ cells as previously described. In addition, samples from thymus 
were double stained with FITC-conjugated anti-human CD4 (clone RPA-T4) 
and PE-conjugated anti-human CD8 (clone SK1). All antibodies were 
purchased from BD Pharmingen (San Diego, CA). 
 
CELL VACCINES AND TREATMENT PROTOCOL 
Cell vaccines 
Humanized mice were enrolled in cell vaccination protocols with human or 
murine cells expressing the antigen human HER-2. In combination with cell 
vaccine administrations, mice received the systemic injection of a potent 
immune adjuvant, recombinant human IL-12 (Nanni et al., 2001). The human 
ovary carcinoma cell line SK-OV-3 positive for human HER-2 was used in a 
formulation of the cell vaccine. The murine cell line used as cell vaccine, and 
here referred as 1E-huHER-2, was kindly provided by Dr S. Pupa (National 
Cancer Institute, Milan). Neu-negative N202.1E cells derived from a mammary 
carcinoma arisen in FVB-NeuN#202 mice (H-2q haplotype) transgenic for the 
rat neu proto-oncogene (Nanni et al., 2000) were transduced with human HER-
2 gene to obtain 1E-huHER-2 cell line. This cell line was routinely cultured in 
DMEM supplemented with 20% FBS and the transgene selection maintained 
with G418 (400 μg/mL). During the culture passage prior to vaccination usage, 
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cells were cultured in medium without selection. Cells were maintained at 37°C 
in a humidified 5% CO2. 
Before the vaccination, SK-OV-3 and 1E-huHER-2 cells were treated with 
120 and 40 µg/ml of mitomycin C (MitC; Sigma-Aldrich), respectively, to 
block cell proliferation. Each vaccination consisted in intraperitoneal (i.p.) 
injection of 2x106 mitomycin C-treated cells in 0.4 mL PBS. Untreated mice 
received only 0.4 ml PBS. 
 
Vaccination protocol 
In humanized Rag2-/-;γc-/- mice, vaccination protocols started at about 7-8 
weeks of age. The vaccination protocol consisted of 4-week cycles: in the first 
2 weeks, mice received four twice-weekly i.p. vaccinations followed by 1 week 
of five daily intraperitoneal administration of recombinant human IL-12 
(PeproTech, Rocky Hill, NJ) (50 ng/mouse each administration during the first 
course, 100ng/mouse thereafter) in 0.2 mL of PBS supplemented with 0.01% 
mouse serum albumin (Sigma Aldrich, St. Louis, MO). The 4th week of the 
cycle is a week of rest. The whole treatment consisted of two cycles of 
vaccination. In each reconstitution experiment, mice were randomized in two 
groups: vaccinated and control mice. 
 
HER2 positive tumor cell challenge in vaccinated mice 
At the end of the second cycle of treatment, vaccinated and control  
Rag2-/-;γc-/- humanized mice received the subcutaneous injection of 105 SK-
OV-3 HER-2+ cells. In the same experimental session, sex- and age-matched 
not humanized naïve Rag2-/-;γc-/- mice received the injection of SK-OV-3 cells 
at the same cell dose. 
Tumor growth was monitored and tumor size measured twice weekly. 
Mice were sacrificed when tumors reached the mean volume of 2 cm3 for 
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humane reasons and lymphoid organs collected, characterized phenotipically 
and for human IFN-γ production (see below). 
 
IMMUNE RESPONSES 
In vitro restimulation of splenocytes through mixed lymphocytes 
tumor cell cultures and IFN-γ release 
Single cell suspensions were prepared from spleen collected from treated 
and control mice. Spleen cell suspensions were subjected to red blood cell lysis. 
Cells were washed in PBS and resuspended in RPMI 1640 supplemented with 
10% FBS. Total mononuclear cells, or enriched human CD45+ cells, purified by 
magnetic sorting (Miltenyi Biotec, Bergisch Gladbach, Germany), were 
cultured (1.2x105 cells/ml) for 6 days at 37°C alone or in the presence of 
proliferation-blocked SK-OV-3 restimulator cells (1.2x104 cells/ml) in RPMI 
1640 supplemented with 10% FBS and with 50 units/ml of recombinant human 
IL-2. The ratio between lymphocytes and target cells was 10:1. Then culture 
supernatants were collected and investigated for the production of human  
IFN-γ  by ELISA assays (Quantikine kit, R&D Systems, Abingdon, UK). 
ELISA assays were performed according to manufacturer instruction, the 
experimental range of detection of human IFN-γ was 1000 - 8 pg/mL. 
 
Detection of human immunoglobulins and antibody response 
To determine if B cells in humanized mice were functional, we assessed 
human antibody production by ELISA according to the manufacturer protocol 
(Bethyl, Montgomery TX). Mice were routinely bled from a tail vein and 
plasma samples collected and stored frozen at -80°C. Briefly, ELISA plates 
were coated overnight with anti-human IgG or IgM capture antibody. Plates 
were washed and blocked for 1-2 hours with a diluent solution. Standard or 
plasma samples, opportunely diluted, were added to the wells and incubated for 
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1 hour. Then plates were washed and incubated with a detection antibody 
conjugated to HRP. The assays were developed with tetramethylbenzidine 
dihydrochloride (TMB) (Thermo Scientific, Rockford, IL). The colorimetric 
reactions were stopped with sulphuric acid. Absorbances of samples were 
measured using a microplate reader (Sunrise TECAN) at 450 nm with a 
reference wavelength of 620 nm. Limits of detections were of 0.016 μg/ml for 
IgM and 0.008 μg/ml for IgG detection assays.  
The production of specific antibodies induced by vaccination was studied 
both by ELISA assay and/or by indirect immunofluorescence assays through 
the binding to huHER-2 positive cells, SK-OV-3, and Western blot assays. 
ELISA assay to detect antibodies recognizing human HER-2 was 
performed in Maxisorp NUNC 96-well microplates as reported. Plates were 
coated with 0.05 μg/well of huECD-HER-2 (human HER-2 extra cellular 
domain) overnight. After 3-4 hours blockade with assay buffer (4% w/v bovine 
serum albumin in PBS), wells were washed three times and incubated two 
hours at room temperature with plasma samples diluted (1:20 – 1:500) in assay 
buffer. Washed plates were then incubated with peroxidase-conjugated goat 
anti-human immunoglobulin G (IgG) IgA, and IgM (IgGAM) antibody 
(Zymed, South San Francisco, CA) for 2 additional hours at room temperature, 
washed again and developed with TMB. A standard curve with anti-huHER-2 
Herceptin monoclonal antibody (kindly provided by Dr. S. Pupa) was run in 
parallel (2 - 0.008 ng/mL).  
For immunofluorescent analysis of anti-human HER-2 antibodies, SK-OV-
3 cells were incubated with plasma at 1:20 dilution for 30 minutes in ice, then 
samples were washed and incubated with a FITC conjugated anti-human IgG or 
anti-human IgM antibody for further 30 minutes in ice. All antibodies were 
purchased from BD Pharmingen. Samples were analyzed with FACScan 
(Becton Dickinson, St Jose, CA).  
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For Western Blot analysis of anti-human HER-2 antibodies, SK-OV-3 cell 
lisates (500 μg/sample) were immunoprecipitated with protein G PLUS-
Agarose (Santa Cruz Biotechnology) after incubation with 1.5 μg of rabbit 
polyclonal anti-p185neu serum C-18 (Santa Cruz Biotechnology, Inc) and 10 μL 
of plasma from vaccinated or control humanized mice. After overnight 
incubation, immune complexes were washed, eluted in Laemmli Sample Buffer 
and denaturated by heating 10 min at 100°C; then samples were resolved in 8% 
polyacrylamide gel. Separated proteins were electrophoretically transferred to 
nitrocellulose membrane (Amersham, UK) and incubated for 1 hour with rabbit 
polyclonal anti-p185neu serum C-18 (1:250) followed by incubation with anti-
rabbit Ig horseradish peroxidase-linked whole antibodies (Santa Cruz 
Biotechnology, Inc) 1:1000 and by a colorimetric reaction (Opti4CN Substrate 
kit; BioRad). 
 
STATISTICAL ANALYSIS 
All statistical analysis were performed with the software Prism (GraphPad 
Software, San Diego, CA, USA). A p-value of <0.05 was considered to be 
statistically significant. 
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